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Abstract 
African trypanosomiasis, a deadly infectious disease caused by the protozoan Trypanosoma brucei spp., 
is spread to new hosts by bites of infected tsetse flies. Currently approved therapies all have their specific 
drawbacks, prompting a search for novel therapeutic agents. T. brucei lacks the enzymes necessary to 
forge the purine ring from amino acid precursors, rendering them dependent on the uptake and 
interconversion of host purines. This dependency renders analogues of purines and corresponding 
nucleosides an interesting source of potential anti-T. brucei agents. In this study, we synthesized and 
evaluated a series of 7-substituted 7-deazainosine derivatives and found that 6-O-alkylated analogues in 
particular showed highly promising in vitro activity with EC50 values in the mid-nanomolar range. SAR 
investigation of the O-alkyl chain showed that antitrypanosomal activity increased, and also cytotoxicity, 
with alkyl chain length, at least in the linear alkyl chain series. However, this could be attenuated by 
introducing a terminal branch point, resulting in the highly potent and selective analogues, 36, 37 and 
38. No resistance related to transporter mediated-uptake could be identified, earmarking several of these 
analogues for further in vivo follow-up studies. 
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Introduction 
Sleeping sickness or human African trypanosomiasis (HAT) is an infectious disease that is classified by 
the WHO as a Neglected Tropical Disease (NTD) and is confined to the African subcontinent. The 
disease-causing pathogen is the protozoan parasite Trypanosoma brucei spp., of which T. b. gambiense 
and T. b. rhodesiense are infectious to humans. Being a vector-transmitted disease, the incidence maps 
geographically with the natural habitats of the tsetse fly, i.e. in sub-Saharan Africa.1  
Currently available therapies are not without limitations, ranging from being ineffective against CNS-
stage disease (pentamidine and suramin), requiring parenteral administration (pentamidine, suramin, 
nifurtimox-eflornithine combination therapy (NECT) and melarsoprol) to inherent toxicity (melarsoprol 
is an organo-arsenical).2-3 These shortcomings add additional layers of difficulty to reach the goal of 
HAT elimination set by the WHO.4-5 Recently, the completion of a phase-2/3 non-inferiority clinical 
trial with fexinidazole6 and subsequent approval of this oral drug for HAT represents new hope for 
patients, as well as people living in regions where they are at risk of contracting the disease. 
Unfortunately, fexinidazole shows cross-resistance to the other nitro group containing drug nifurtimox.7-
8 Additionally, fexinidazole treatment suffers from a high pill burden,6 highlighting the need for further 
drug discovery efforts to identify new potential chemotherapeutic intervention options.1, 9 
African trypanosomes markedly differ from their mammalian hosts with respect to the means by which 
they meet their demand for purine and purine nucleoside building blocks, which they need in great 
quantities to sustain their high replication rate. These parasites lack the enzymes for de novo purine 
synthesis from amino acid precursors and therefore depend on uptake and subsequent interconversion 
of available purines from the host.10-11 T. brucei is capable of growing on virtually every purine source, 
showing a large degree of possible interconversion in the purine salvage pathway enzymatic 
machinery.12-15 This biochemical difference between parasite and host could be leveraged to discover 
purine and purine nucleoside analogues with antitrypanosomal activities,11 a strategy that already 
afforded several promising derivatives, such as tubercidin (2)11, 14 and cordycepin (4, Figure 1),14, 16 two 
so-called naturally occurring ‘nucleoside antibiotics’. However, tubercidin suffers from high toxicity 
against mammalian cells17 and cordycepin is readily deaminated18 to the corresponding 3’-deoxyinosine, 
which displays much weaker anti-T. brucei activity.16, 18-19 
Recently, our group has re-examined tubercidin (7-deazaadenosine) and several 7-substituted 
analogues.17 Although the cytotoxicity of tubercidin is impairing its further development as a 
trypanocide, we demonstrated that the introduction of aromatic substituents at position 7 conferred 
potent antitrypanosomal activity while reducing cytotoxicity (e.g. analogue 3). Furthermore, the 
combination of structural elements of tubercidin (in casu its 7-deazapurine nucleobase) with the sugar 
ring of cordycepin (3’-deoxyadenosine), led to the discovery of the highly potent antitrypanosomal agent 
5, which was able to clear an established CNS-stage infection in mice.20 These examples showcase the 
potential of purine nucleoside analogues to identify potent (and selective) antitrypanosomal agents.   
 
 
Figure 1: Overview of reported purine nucleoside analogues with activity against African trypanosomes. 
 
The analogues mentioned above are all structurally related to adenosine, being 6-aminopurine or 7-
deazapurine nucleosides (Figure 1, upper line), while on the other hand, derivatives related to their 6-
oxo congener inosine (Figure 1, lower line), have been less extensively explored. Nonetheless, previous 
studies identified several potent inosine-like nucleoside analogues with interesting anti-T. brucei 
activity,21-23 of which 9-deazainosine (8)22, 24 and Formycin B (9)22, 25 are noteworthy. Recently, 7-cyano-
7-deazainosine has been discovered as a potent activator of T. brucei protein kinase A (PKA), albeit that 
it did not display antitrypanosomal effects in vitro.26  
Inosine(-like) nucleosides, are preferentially taken up by the trypanosomal P1-nucleoside transporter, 
which can be inferred from previously described recognition elements for the P1 and P2 transporter 
systems.10, 27-29 This would constitute a significant benefit regarding the development of 
(cross-)resistance, as several adenosine(-like) nucleoside analogues have been shown to be 
predominantly concentrated inside the trypanosome by the P2 transporter,19, 28 which is encoded by a 
single non-essential gene,30 and therefore represents a known resistance factor (also vide infra).31-33 
Building on our recent discovery of 7-substituted 7-deazaadenosine analogues as potent anti-T. brucei 
agents,17 we became interested in the evaluation of 7-substituted inosine nucleoside analogues. In the 
present manuscript, we elaborate on their synthesis and assess their anti-T. brucei activity against T. b. 
brucei and T. b. rhodesiense. Additionally, we provide in vitro data on P2 knock-out T. brucei parasites, 
demonstrating that this transporter does not significantly contribute to drug sensitivity, thereby rendering 
the development of cross-resistance with diamidine and melaminophenyl arsenical drugs such as 
pentamidine, diminazene or melarsoprol unlikely. 
 
 
 
 
 
 
Results and discussion 
Chemistry 
The synthesis of nucleoside analogues 7-46 is depicted in Scheme 1-4. 7-Deazainosine derivatives 11-
14 were prepared employing Vorbrüggen glycosylation of appropriately substituted pyrrolo[2,3-
b]pyrimidines with commercially available 1-O-acetyl-tri-O-benzoylribofuranose (Scheme 1).34 Then, 
the 6-chloride was displaced with sodium methoxide, which also cleaved the benzoyl protecting groups. 
The 6-oxo group was revealed by either TMSI-mediated demethylation or nucleophilic displacement 
with NaOH. To obtain 7-deazainosine 7, the 7-iodide was removed from 50 by halogen/magnesium 
exchange with Knochel’s Turbo Grignard reagent,35-36 followed by protic quench. One-pot nucleophilic 
aromatic substitution and deprotection with aqueous NaOH furnished 7. The 7-trifluoromethyl 
substituted analogue 15 was prepared by reacting 50 with in situ prepared CuCF3 in DMF/NMP, 
employing the method we recently reported for related pyrrolo[2,3-b]pyridine nucleoside analogues.37 
7-Aryl substituents were introduced on 25 by Suzuki reaction.17, 38-39 Analogue 26 was then 
demethylated to give inosine analogue 16. 
 
 Scheme 1: Reagents and conditions: 5-substituted pyrrolo[2,3-d]pyrimidine (X=F,40-41 Cl,42 Br42 or I42), 
BSA, TMSOTf, MeCN, 80 °C; b) NaOMe, MeOH, 65% (F), 57% (Cl), 67% (Br), 54% (I); c) TMSCl, 
NaI, MeCN, 67% (11), 80% (2 steps, 15), 58% (16); d) 2M aq. NaOH, 1,4-dioxane, reflux, 55% (7), 
33% (12), 58% (13), 54% (14); e) i. 1.3M iPrMgCl.LiCl/THF, THF; ii. iPrOH; f) TMSCF3, CuI, KF, 
NMP/DMF (1:1), 36%; g) arylboronic acid, Na2CO3, Pd(OAc)2, TPPTS, MeCN/water (1/2), 100 °C, 
91% (26), 33% (27). 
 
Nucleosides with a 2-substituted 6-oxo-7-deazapurine purine ring 17-19 (Scheme 2) were either 
synthesized via Vorbrüggen coupling 43 (19) or anion glycosylation44 (20, 21 and 59), followed by 
removal of all sugar protecting groups, and additional nucleophilic aromatic substitution for 19. The 6-
chloride of 20 was removed by hydrogenation with Pd/C, to give 22, or substituted with NaOH to give 
18.  In order to prepare derivative 17, nucleophilic aromatic substitution with NaOH was first attempted 
on 59, which unexpectedly failed to deliver any of the desired product. Therefore, 59 was first converted 
into its corresponding 6-amino analogue 60 in a sequence that employed substitution with NaN3 and 
Staudinger reduction under conditions that were reported previously,45-47 albeit that an elevated 
temperature and prolonged reaction time were required to effect 6-substitution. Then, a diazotization 
reaction on 60 furnished the desired 2-methyl substituted 7-deazainosine derivative 17. 
 
 
Scheme 2: Reagents and conditions: a) 2-pivaloylamino-4-chloro-5-bromo-7H-pyrrolo[2,3-
d]pyrimidine,43, 48 BSA, TMSOTf, MeCN, 50 °C, 65 %; b) NaOMe, MeOH, reflux, 56 %; c) 2M aq. 
NaOH, 1,4-dioxane, reflux, 54 %; d) i. P(NMe2)3, CCl4, THF, -78 °C; ii) 2-amino-4-chloro-7H-
pyrrolo[2,3-d]pyrimidine or 2-amino-4-chloro-5-bromo-7H-pyrrolo[2,3-d]pyrimidine43 or 2-methyl-4-
chloro-7H-pyrrolo[2,3-d]pyrimidine,35, 49 NaH, MeCN, 47% (56), 37% (57), 48% (58); e) 95% aq. TFA, 
48% (20), 59% (21), 43% (59); f) Pd/C, H2, NaOAc, MeOH; g) aq. NaOH, 1,4-dioxane; h) i. NaN3, 
DMF, 80 °C; ii. 1M PMe3 in THF, water, 62 % (2 steps); i) NaNO2, AcOH, water, 64%. 
The synthesis of various 6-O-alkyl substituted nucleoside analogues (29 – 40, Scheme 3) was achieved 
by suspending intermediate 48 in the appropriate alcohol and treating it with the corresponding alkoxide, 
prepared by dissolving metallic sodium in said alcohol or by treating it with NaOtBu. 
 
 
Scheme 3: Reagents and conditions: a) RONa, ROH, 20 – 80 %. 
 
The synthesis of 3’-deoxyribofuranose nucleoside analogues is depicted in Scheme 4. Analogues 42 and 
45 were prepared from 520, 50, via a two-step one pot sequence. The 6-amino group was transformed into 
a 1,2,4-triazol-4-yl leaving group,51-52 with 61 (prepared from DMF and SOCl2),52-53 and directly 
converted to the desired nucleoside analogues 42 and 45. Alternatively, the 7-bromo functionalized 
derivative 739 was reacted with sodium methoxide yielding 46, which after TMSI-mediated 
demethylation gave rise to 3’-deoxyinosine analogue 43. 3’-Deoxyinosine (41) and 3’-deoxy-7-
deazaguanosine (44) were prepared from the corresponding ribonucleosides, in a three-step sequence. 
First, the vicinal diol was transformed into the 3’-xylo-iodide upon reaction with α-
acetoxyisobutyrylchloride in the presence of NaI.50, 54-55 Then, de-iodination was effected by catalytic 
hydrogenation with Pd(OH)2/C, after which ammonolysis furnished the desired analogues. 
 
 Scheme 4: Reagents and conditions: a) 1. SOCl2, aq. NH2NH2; 2. aq. NaOH; b) 61, TMSCl, pyridine, 
reflux; c) appropriate nucleophile: 1M aq. NaOH, 20 % (42); 0.5M NaOMe/MeOH, 66 % (45); d) 
NaOMe, MeOH, 50 °C, 69 %; e) NaI, TMSCl, MeCN, rt, 21 %; f) i) α-acetoxyisobutyryl chloride, NaI, 
MeCN, ii) Pd(OH)2/C, H2, NaOAc, MeOH, iii) 7N NH3, MeOH, 33% (41), 21% (44). 
 
Biological evaluation 
All final nucleoside analogues were evaluated in vitro against T. b. brucei and T. b. rhodesiense, and 
assayed for cytotoxicity in MRC-5 human fibroblasts. The results are depicted in Table 1-3. 
 
Cpd. 
R  
/ 
 structure 
T. b. brucei  
EC50 (µM) 
T. b. 
rhodesiense  
EC50 (µM) 
MRC-5  
EC50 (µM) 
SI  
T. brucei 
 
SI  
T. brucei 
rhod. 
 
Inosine analogues 
7 H 4.2 ± 0.85 19.1 ± 0.4 31.3 ± 1.6 7.4 1.6 
11 F 0.10 ± 0.01 1.06 ± 0.07 2.03 ± 0.64 21 1.9 
12 Cl 10.7 ± 3.1 25.1 ± 3.0 >64.0 6.0 2.5 
13 Br 52.4 ± 11.7 29.2 ± 0.8 >64.0 1.2 2.2 
14 I 57.3 ± 6.7 23.9 ± 1.1 >64.0 1.1 2.7 
15 CF3 >64.0 10.9 3.28 0.1 0.3 
16 phenyl 32.2 9.4 >64.0 >2 >6.8 
17 
 
>64.0 4.7 >64.0 -- >13 
Guanosine analogues 
18 H >64.0 12.9 >64.0 -- >5.0 
19 Br 2.01 ± 0.04 0.49 ± 0.01 >64.0 >31 >130 
20 
 
0.49 ± 0.004 0.18 ± 0.08 >64.0 >131 >347 
21 
 
0.13 ± 0.003 0.047 ± 0.023 40.2 ± 9.6 316 847 
22 
 
>64.0 >64.0 >64.0 -- -- 
Suramin -- 0.028 ± 0.009 0.033 ± 0.005 ND -- -- 
Table 1: Evaluation of drug sensitivity of nucleoside analogues against bloodstream forms of T. b. 
brucei and T. b. rhodesiense. Cytotoxicity was assayed against the human MRC-5 fibroblast cell line. 
Values represent mean ± SEM, which originated from 2–3 independent experiments and are expressed 
in µM. Values in italics represent the result of a single determination. SI, in vitro selectivity index, being 
the ratio of the EC50 for the MRC-5 cells and the EC50 of the trypanosome species. 
 
Our investigation started with 7-deazainosine (7, Table 1), which was previously reported to exhibit 
antitrypanosomal effects.21 This analogue exhibited low micromolar in vitro potency (EC50 = 4.2 ± 0.85 
µM) against T. b. brucei and was only moderately active against T. b. rhodesiense, which prompted the 
evaluation of several 7-substituted analogues (11-16). Introduction of a halogen atom in the 7-position 
led to a significant loss of activity, with the exception of 7-fluoro substituted analogue (11), although 
this derivative also displayed significant cytotoxicity against MRC-5 fibroblasts. The addition of a 
phenyl ring (16), nor a trifluoromethyl group (15) was able to produce any improvement of the in vitro 
antitrypanosomal activity, which contrasts with the observed SAR for the corresponding 6-aminopurine 
nucleoside analogues.17 
The introduction of a substituent in the 2-position such as a methyl (17) or an amino group (giving rise 
to guanosine analogue 18), revealed that neither was tolerated. On the other hand, adding a 7-bromide 
to 7-deazaguanosine 18 did restore antitrypanosomal activity (i.e. analogue 19), and this analogue also 
lacked in vitro cytotoxicity against MRC-5 cells. Interestingly, the evaluation of synthetic intermediates 
20 and 21 having a 6-chloride, showed remarkable antitrypanosomal activity with excellent selectivity 
indexes. Removal of the 6-substituent of 20 (i.e. analogue 22) resulted in the complete loss of any in 
vitro activity against either trypanosome species. These results led us to evaluate 6-OMe substituted 
nucleoside analogues 23-25 and 26 (Table 2), which were prepared en route to the inosine analogues. 
All three halogenated analogues (23, 24 and 25) displayed sub-micromolar potency against T. brucei 
parasites (Table 2), while having virtually no cytotoxicity. On the 7-deaza-6-O-methylinosine scaffold, 
a 7-phenyl group or a 7-para-chlorophenyl substituent was not tolerated. Analogue 28 also showed sub-
micromolar antitrypanosomal activity, albeit with only modest selectivity. Encouraged by the results 
with the 6-O-methylated analogues, we decided to further explore the SAR in this series by varying the 
6-O-alkyl group. In this series, we chose a chloride as the preferred substituent in the 7-position, as we 
reasoned that such derivatives might potentially be chemically more stable than the 7-bromide and 7-
iodide equivalents.  
 
 
Cpd. 
R or X  
/  
Structure 
T. b. brucei  
EC50 (µM) 
T. b. 
rhodesiense  
EC50 (µM) 
MRC-5  
EC50 (µM) 
SI  
T. 
brucei 
 
SI  
T. 
brucei 
rhod. 
 
23 X=Cl 0.16 ± 0.02 0.036 ± 0.003 [32.0; >64] >200 >888 
24 X=Br 0.19 ± 0.02 0.036 ± 0.003 >64.0 >336 >1777 
25 X=I 0.22 ± 0.004 0.053 ± 0.003 38.4 ± 1.0 168 708 
26 X=Phe >64.0 >64.0 >64.0 -- -- 
27 X=4Cl-Phe >64.0 22.3 61.1 -- 2.7 
28 
 
0.13 ± 0.00 0.077 ± 0.007 3.24 ± 0.01 24 42 
29 R=ethyl 0.12 ± 0.01 0.057 ± 0.04 [33.0; >64] >275 >578 
30 R=propyl 0.081 ± 0.05 0.076 ± 0.050 2.81 ± 1.6 34 37 
31 R=butyl 0.069 ± 0.040 0.036 ± 0.010 1.32 ± 0.09 19 37 
32 R=pentyl 0.088 ± 0.026 0.032 ± 0.001 0.10 ± 0.03 1.1 3.2 
33 R=ethyl-phenyl 0.095 ± 0.03 0.030 ± 0.002 0.31 ± 0.42 3.3 10.3 
34 
R=2-methoxy-
ethyl 
0.17 ± 0.03 0.22 ± 0.07 4.13 ± 1.5 25 18.8 
35 
R=2-phenoxy-
ethyl 
0.13 ± 0.009 0.16 ± 0.05 43.2 ± 20.8 329 263 
36 R=i-propyl 0.090 ± 0.04 0.10 ± 0.08 >64.0 >711 >640 
37 R=i-butyl 0.071 ± 0.041 0.030 ± 0.0004 49.5 ± 14.6 694 1671 
38 R=i-pentyl 0.058 ± 0.028 0.029 ± 0.0008 >64.0 >1099 >2195 
39 R=c-pentyl 0.20 ± 0.0008 0.12 ± 0.003 38.1 ± 20.0 191 326 
40 R=c-hexyl 0.40 ± 0.03 0.38 ± 0.13 >64.0 >161 >168 
Suramin -- 0.028 ± 0.009 0.033 ± 0.005 ND -- -- 
Table 2: Evaluation of drug sensitivity of nucleoside analogues against bloodstream forms of T. b. 
brucei and T. b. rhodesiense. Cytotoxicity was assayed against the human MRC-5 fibroblast cell line. 
Values represent mean ± SEM, which originated from 2–3 independent experiments and are expressed 
in µM. SI, in vitro selectivity index, being the ratio of the EC50 for the MRC-5 cells and the EC50 of the 
trypanosome species. 
 
Varying the length of the 6-O-alkyl group from methyl (23) to pentyl (32) showed that antitrypanosomal 
activity increased with the chain length. Unfortunately, the selectivity dropped progressively to almost 
none when the n-alkyl group was larger than two carbon units. The introduction of an extra phenyl group 
(2-phenylethyl analogue 33) increased anti-T. brucei potency relative to the O-ethyl analogue 29, but 
this compound also displayed cytotoxicity at sub-micromolar concentrations. The 2-methoxyethyl 
analogue 34 actually displayed identical activity as the ethyl analogue, but again with lower selectivity, 
whereas the 2-phenoxyethyl analogue 35 actually had a favourable SI, with comparable 
antitrypanosomal activity to the O-ethyl analogue 29. 
For branched-chain alkyl groups, the antitrypanosomal activity also increased with growing chain length 
(EC50 = 0.090 µM for i-propyl 36 to EC50 = 0.058 µM for i-pentyl 38), but in contrast to the linear alkyl 
groups the selectivity index remained very high, as compounds displayed virtually no cytotoxicity 
against MRC-5 fibroblast cells. Finally, cyclic alkyl groups 39 (c-pentyl) and 40 (c-hexyl), which can 
be considered as modified isopropyl analogues, did not display increased antitrypanosomal activity with 
respect to 36, but the toxicity remained very low. From this SAR exploration, analogue 38 appeared as 
most potent, with a roughly three-fold increase in in vitro anti-T. brucei activity, compared to the initially 
discovered 23. 
Finally, we investigated the effects of removing the hydroxyl group at the  3’-position of the sugar 
moiety, a strategy that in the 7-deazaadenosine series led to a significant increase in antitrypanosomal 
activity.20, 39 3’-Deoxyinosine23 41 was confirmed to elicit low micromolar activity against T. brucei 
(Table 3). In the case of 7-deazainosine (7), however, 3’-deoxygenation (i.e. analogue 42), failed to 
improve antitrypanosomal activity. Interestingly, the addition of a 7-bromide led to an increase in in 
vitro activity regardless of 3’-deoxygenation (compare matched pairs 7 vs. 13 (Table 1) and 42 vs. 43), 
while for the 6-O-alkylated derivatives removal of the 3’-hydroxyl group was clearly not tolerated 
(compare 24 vs. 46).   
 
Cpd. Structure 
T. b. brucei  
EC50 (µM) 
T. b. 
rhodesiense  
EC50 (µM) 
MRC-5  
EC50 (µM) 
SI  
T. brucei 
 
SI  
T. brucei 
rhod. 
 
41 
 
1.1 ±  0.2 6.7 ±  0.6 >64.0 56.1 9.5 
42 
 
29.6 ± 0.1 2.9 ± 0.8 >64.0 >2 >22 
43 
 
8.1 ± 0.03 2.3 ± 0.1 >64.0 >7 >28 
44 
 
>64.0 >64.0 >64.0 -- -- 
45 
 
>64.0 >64.0 >64.0 -- -- 
46 
 
2.6 ± 0.6   3.7 ± 1.6 2.7 ± 1.1 1 0.7 
Suramin -- 0.028 ± 0.009 0.033 ± 0.005 ND -- -- 
Evaluation of drug sensitivity of nucleoside analogues against bloodstream forms of T. b. brucei and T. 
b. rhodesiense. Cytotoxicity was assayed against the human MRC-5 fibroblast cell line. Values represent 
mean ± SEM, which originated from 2–3 independent experiments and are expressed in µM. Values in 
italics represent the result of a single determination. SI, in vitro selectivity index, being the ratio of the 
EC50 for the MRC-5 cells and the EC50 of the trypanosome species. 
 
To further investigate the potential of these analogues as trypanocides, we assayed selected analogues 
against a panel of drug resistant T. brucei strains (TbAT1-KO, B48 and ISMR1; Table 4). Given the 
polar nature of nucleoside analogues, their uptake by T. brucei parasites is expected to be mediated by 
purine transporters with no significant contribution from simple diffusion.10 When the relevant 
transporter is non-essential for survival of the parasite, as is the case for the P2 aminopurine 
transporter,30-31 it constitutes a potential resistance factor. Comparison of the potency of 23, 24, 29 and 
36 for wild-type (Lister-427) versus TbAT1-KO and B48 cell lines (both of which lack the P2 
transporter), revealed that the activity of none of these analogues is greatly impacted by the loss of the 
P2 transporter, particularly when compared to tubercidin (7-deazaadenosine), which is greatly impacted 
by the loss of the transporter.17, 28 Based on known recognition elements for both P1 and P2 transporter 
systems,10, 27-29 it would indeed seem unlikely that these O-alkylated inosine analogues are good 
substrates for the P2 transporter, which mainly recognizes an amidine or amidine-like moiety, as present 
in pentamidine, diminazene, the melamine moiety of melarsoprol and 6-aminopurines.  
 
Table 4: In vitro anti-trypanosomal evaluation against three drug-resistant T. b. brucei cell lines. EC50 
values are given as the mean and SEM of three independent determinations (in µM).  RF = Resistance 
factor: ratio of EC50 between resistant and reference (Lister-427) cell line. TbAT1-KO: T. brucei cell 
line lacking the TbAT1/P2 transporter gene. B48: pentamidine, diminazene and melaminophenyl 
Compound 
Lister-427 
 EC50 (µM) 
TbAT1-KO  
EC50 (µM) 
RF 
B48   
EC50 (µM) 
RF 
ISMR1  
EC50 (µM) 
RF 
Tubercidin, 217  0.15 ± 0.03 2.61 ± 0.70 17.2 4.3 ± 1.3 28.7 1.7 ± 0.5 11.1 
23 0.10 ± 0.01 0.057 ± 0.005 0.57 
0.057 ± 
0.002 
0.57 
0.084 ± 
0.015 
0.84 
24 0.117 ± 0.006 0.083 ± 0.013 0.71 
0.090 ± 
0.010 
0.77 
0.099 ± 
0.016 
0.85 
29 0.079 ± 0.006 0.113 ± 0.011 1.43 
0.134 ± 
0.007 
1.70 
0.194 ± 
0.037 
2.45 
36 0.184 ± 0.008 0.198 ± 0.014 1.08 
0.188 ± 
0.014 
1.02 
0.27 ± 
0.01 
1.47 
Pentamidine 0.011 ± 0.001 0.018 ± 0.002 1.8 0.99 ± 0.16 94.6 
0.14 ± 
0.04 
13.8 
Diminazene 0.42 ± 0.06 4.5 ± 0.9 10.6 7.2 ± 1.6 16.9 2.9 ± 0.4 6.9 
Isometamidium 0.65 ± 0.09 0.75 ± 0.14 1.2 0.56 ± 0.13 0.85 3.1 ± 0.5 4.8 
arsenical resistant cell line. ISMR1: isometamidium resistant cell line. The reported values for tubercidin 
were taken from reference 27. 
 
Next, to gain a more in-depth understanding of the potential interaction of these analogues (23, 29 and 
36) with the P1 and/or P2 transporter, we performed competition experiments with [3H]-adenosine 
(Figure 2 and Table 5). In order to measure P1-mediated uptake, B48 cells were employed, which lack 
the P2 transporter. Uptake via the P2 transporter was measured in a B48 cell line that stably 
overexpresses TbAT1, and uptake experiments were performed in the presence of 100 µM inosine to 
block P1-mediated transport.56 
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Figure 2: Transporter binding experiments of selected nucleoside analogues with P1 and P2 of 
bloodstream form T. brucei. The transport of 50 nM [3H]-adenosine by bloodstream forms of T. b. brucei 
strain B48 (panel P1) or B48 expressing TbAT1/P2 (panel P2) was measured in the absence or presence 
of increasing concentration of nucleoside analogues. The panels each show a single experiment, 
performed in triplicate, that is representative of three identical but independent experiments. Error bars 
are SEM and when not shown fall within the symbol. 
 
 
 
Compound 
P1 transporter P2 transporter 
Km or Ki ΔG0 δ(ΔG0) Km or Ki ΔG0 δ(ΔG0) 
Adenosine 0.12 ± 0.02 -39.4  -- 0.53 ± 0.02 -35.8 --  
Tubercidin, 227 78 ± 6.4 -23.4 15.4 3.8 ± 0.7 -30.9 4.9 
23 35.5 ± 4.1 -25.4 14.0 149.0 ± 26.0 -21.8 14.0 
29 99.0 ± 9.1 -22.9 16.5 138.8 ± 20.8 -22.0 13.8 
36 284.5 ± 29.7 -20.6 19.2 245.7 ± 49.5 -20.6 15.2 
Table 5: Kinetic parameters for P1 and P2 mediated uptake of selected nucleoside analogues (also see 
Figure 2). Km (bold) or Ki values are given in µM, and ΔG0 in kJ/mol. δ(ΔG0) was calculated with respect 
to the value for adenosine. The reported values for tubercidin were taken from reference 27. 
 
From the uptake experiments it was shown that none of the O-alkylated analogues was a good P1 
substrate, since all three analogues lost ≥14 kJ/mol in binding affinity compared to adenosine (Table 5). 
This indicates the loss of at least one H-bond interaction with the transporter, and is somewhat 
unexpected given the presence of three recognition elements: OH-3’, OH-5’ and N-3.27 Indeed, the 
nitrogen atom in the 7-position, considered to be the fourth recognition element, has been replaced by a 
substituted carbon (compare with tubercidin, 2), but we have previously found the addition of a halogen 
or heteroaryl group in this position to be able to restore, at least partially, P1-binding in 6-aminopurine 
nucleoside analogues.17, 20 This holds true for 23, but not for analogues 29 and 36, which have a larger 
6-O-alkyl substituent. It is noteworthy that the gradual increase in steric bulk at the 6-position impacted 
P1-transporter engagement to such an extent (Ki O-Me < O-Eth < O-iPr). We therefore hypothesize that 
a steric clash with the transporter protein is responsible for the reduced P1 binding affinity, even for 23, 
having a 6-OMe substituent. A similar observation was made in a study on C2/N6 disubstituted 
adenosine analogues,57 albeit that the presence of a 2-substituent in these two analogues confounds a 
direct matched pair analysis.  
Concerning P2-mediated uptake, all three assayed analogues displayed affinities in the high micromolar 
range, which is expected, as the main recognition element for P2, being the N1-C6-NH2 amidine 
functionality, has been replaced. The binding affinity for the i-propyl-substituted analogue 36 was found 
to be somewhat lower than that of the other two analogues (~1.4 kJ/mol), but this difference was less 
pronounced than the equivalent δ(ΔG0) observed for the P1 transporter.  
 
Conclusion 
In the present study, we have investigated the antitrypanosomal effects of a series of 7-deazainosine 
nucleoside analogues. It was found that 7-substituted 7-deazainosine analogues had weak in vitro 
activity against T. brucei parasites. However, 6-O-Alkylated 7-deazainosine analogues which were 
prepared as synthetic intermediates, proved highly active trypanocides. Structure-activity relationship 
investigation pointed out that the size of the alkyl group positively correlated with anti-T. brucei activity, 
but so did the cytotoxicity against mammalian cells in the n-alkyl series. This could be circumvented by 
introducing an alkyl chain branch, identifying a 6-O-isopentyl substituent (derivative 38) as the most 
potent analogue, while being completely devoid of toxicity against MRC-5 fibroblast cells at the highest 
concentration tested. Additionally, we have shown that these O-alkylated inosine derivatives are 
preferentially taken up by the P1 transporter, and hence do not suffer from P2-transporter based (cross)-
resistance with other nucleoside analogues such as tuberidin or clinically used diamidines and 
melaminophenyl arsenicals. Several analogues identified in this work are now ready to proceed to 
evaluation in animal models of HAT. 
 
 
 
 
 
Experimental section 
Chemistry 
Reagents and solvents were obtained from commercial sources of analytical grade. Unless otherwise 
specified, they were used as received. Nucleoside derivatives 520, 4734, 4834, 4934, 5034 and 6239 were 
prepared according to published procedures. Moisture sensitive reactions were performed under either 
argon or nitrogen atmosphere. Unless otherwise described, reactions were carried out at ambient 
temperature. Analytical TLC analysis to monitor reactions was performed on Machery-Nagel® 
precoated F254 aluminum plates. Plates were visualized by UV followed by development by basic aq. 
KMnO4 or sulfuric acid-anisaldehyde spray. Column chromatography was performed using Macherey-
Nagel® 60M silica (40-63 µm) or on a Reveleris X2 (Grace/Büchi) automated Flash unit, with pre-
packed silica columns. NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer. 
Chemical shifts (δ) are given in ppm and spectra are referenced to the residual solvent peak. Coupling 
constants are given in Hz. ). For 19F-NMR spectra, signals were referenced to the lock resonance 
frequency of CDCl3 or DMSO-d6, according to IUPAC referencing (CFCl3 set to δ = 0 ppm). Exact mass 
measurements were done on a Waters LCT Premier XE™ Time of Flight (ToF) mass spectrometer with 
a standard electrospray (ESI) and modular Lockspray™ interface. Samples were infused in a 
MeCN/water (1:1) + 0.1 % formic acid mixture at 100 µL/min. Melting points were determined on a 
Büchi-545 apparatus and are uncorrected. Purity of all final compounds was assessed by means of 
analytical LC-MS on a Waters AutoPurification system with an ACQUITY QDa (mass; 100 – 1000 
amu) and 2998 Photodiode Array (220 – 400 nm) using a Waters Cortecs® C18 (2.7 µm 100x4.6mm) 
column. A standard gradient consisting of HCOOH in H2O (0.2 %, v/v)/MeCN at a flow rate of 1.44 
mL/min, 95:05 to 00:100 in 6.5 minutes was used for all samples. All obtained final compounds had 
purity > 95 %, as assayed by analytical HPLC (UV); unless otherwise specifically mentioned.  
 
4-Oxo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (7)58 52 (0.30 g, 0.50 mmol) was dissolved 
in 1,4-dioxane (2 mL). 2 N aq. NaOH (2 mL) was added, and the reaction was heated to reflux. After 2 
hours, the reaction was cooled down to room temperature and neutralized to pH 7 via the addition of 4 
M aq. HCl. Celite® (2 g) was added, the mixture concentrated in vacuo, and the residue purified by 
flash column chromatography (2 → 20% MeOH/DCM) to afford 7 as a white solid (0.093 g, 0.35 mmol) 
in 55% yield over 2 steps (starting from 50). 1H NMR (300 MHz, DMSO-d6) δ 3.47 - 3.75 (2H, m, H-
5’, H-5’’), 3.88 (dd, J = 7.3, 3.8 Hz, 1H, H-4’), 3.98 - 4.11 (m, 1H, H-3’), 4.24 - 4.42 (m, 1H, H-2’), 
5.01 (t, J = 5.0 Hz, 1H, OH-5’), 5.13 (br. s., 1H, OH-2’), 5.31 (br. s., 1H, OH-3’), 6.02 (d, J = 6.2 Hz, 
1H, H-1’), 6.53 (d, J = 3.5 Hz, 1H, H-7), 7.37 (d, J = 3.5 Hz, 1H, H-6), 7.91 (s, 1H, H-2), 11.89 (br. s, 
1H, NH). Spectral data are in accordance with literature values.58 
4-Oxo-5-fluoro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (11)34 51 (0.078 g, 0.26 mmol, 1.0 
eq.) was dissolved in MeCN (5 mL). NaI (0.20 g, 1.3 mmol, 5.0 eq.) was added, followed by TMSCl 
(0.16 mL, 1.3 mmol, 5.0 eq.). The reaction was stirred for 3 h at room temperature, neutralized via the 
addition of aq. sat. NaHCO3 (1 mL), and diluted with MeOH. Celite ® (2 g) was added, and the mixture 
was concentrated in vacuo. The residue was purified by flash column chromatography (5 → 20% 
MeOH/DCM) to afford 11 as a white solid (0.050 g, 0.18 mmol, 67%). 1H NMR (300 MHz, DMSO-d6) 
δ 3.44 - 3.68 (m, 2H, H-5’, H-5’’), 3.86 (dd, J = 7.3, 3.8 Hz, 1H, H-4’), 3.98 - 4.10 (m, 1H, H-3’), 4.23 
(s, 1H, H-2’), 5.01 (t, J = 5.0 Hz, 1H, OH-5’), 5.14 (br. s., 1H, OH-2’), 5.34 (br. s, 1H, OH-3’), 6.06 (dd, 
J = 6.0, 1.9 Hz, 1H, H-1’), 7.33 (d, J = 1.8 Hz, 1H, H-6), 7.92 (s, 1H, H-2), 12.05 (br. s, 1H, NH) ppm. 
Spectral data are in accordance with literature values.34 
4-Oxo-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (12)34 23 (0.080 g, 0.25 mmol, 1 
eq.) was suspended in 1,4-dioxane (4.0 mL, 13.3 mL/mmol SM) and 2 M aq. NaOH solution (15 mL, 
89 mL/mmol SM) was added. The resulting mixture was refluxed for 4 h and cooled to ambient 
temperature. After neutralization with 3 M aq. HCl solution the mixture was evaporated till dryness, re-
suspended in MeOH and adsorbed onto Celite®. Purification by column chromatography (8 → 20 % 
MeOH/DCM) gave 12 (0.025 g, 0.083 mmol) as a white powder in 33 % yield. 1H NMR (300 MHz, 
DMSO-d6) δ: 3.53 (ddd, J = 12.0, 4.8, 4.2 Hz, 1H, H-5’’), 3.61 (ddd, J = 12.0, 5.1, 3.9 Hz, 1H, H-5’), 
3.88 (dd, J = 6.9, 3.9 Hz, 1H, H-4’), 4.04 – 4.08 (m, 1H, H-3’), 4.27 (q, J = 5.7 Hz, 1H, H-2’), 5.04 (t, 
J = 5.4 Hz, 1H, OH-5’), 5.14 (d, J = 4.8 Hz, 1H, OH-3’), 5.36 (d, J = 6.0 Hz, 1H, OH-2’), 6.02 (d, J = 
5.7 Hz, 1H, H-1’), 7.53 (s, 1H, H-6), 7.94 (s, 1H, H-2), 12.11 (s, 1H, NH). Spectral data are in accordance 
with literature values.34 
4-Oxo-5-bromo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (13)34 24 (0.033 g, 0.090 mmol, 
1.0 eq.) was dissolved in 1,4-dioxane (2 mL). 2 N aq. NaOH (2 mL) was added, and the reaction was 
heated to reflux. After 2 h, the reaction was cooled down to room temperature and neutralized to pH 7 
via the addition of 4 M aq. HCl. Celite® (2 g) was added, the mixture concentrated in vacuo. The residue 
was purified by flash column chromatography (10% MeOH → DCM and 20% MeOH/DCM) to afford 
13 as a white solid (0.018 g, 0.050 mmol) in 58% yield. 1H NMR (300 MHz, DMSO-d6) δ 3.45 - 3.73 
(m, 2H, H-5’, H-5’’), 3.88 (d, J = 3.5 Hz, 1H, H-4’), 4.06 (dd, J = 8.2, 4.7 Hz, 1H, H3’), 4.28 (dd, J = 
6.2, 5.3 Hz, 1H, H2’), 5.05 (t, J = 5.4 Hz, 1H, OH-5’), 5.15 (d, J = 5.0 Hz, 1H, OH-2’), 5.37 (d, J = 6.2 
Hz, 1H, OH-3’), 6.01 (d, J = 6.2 Hz, 1H, H-1’), 7.56 (s, 1H, H-6), 7.94 (s, 1H, H-2), 12.04 (br. s, 1H, 
NH) ppm. Spectral data are in accordance with literature values.34 
4-Oxo-5-iodo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (14)34 50 (0.27 g, 0.37 mmol) was 
dissolved in 1,4-dioxane (2 mL). 2 N aq. NaOH (2 mL) was added, and the reaction was heated to reflux. 
After 2 hours, the reaction was cooled down to room temperature and neutralized to pH 7 via the addition 
of 4M aq. HCl. Celite® (2 g) was added, the mixture concentrated in vacuo, and the residue purified by 
flash column chromatography twice (first 8% MeOH/DCM and 25% MeOH/DCM; then 2 → 20% 
MeOH/DCM) to afford 14 as a white solid (0.080 g, 0.20 mmol) in 54% yield. 1H NMR (300 MHz, 
DMSO-d6) δ 3.48 - 3.67 (m, 2H, H-5’, H-5’’), 3.87 (dd, J = 7.0, 3.8 Hz, 1H, H-4’), 3.99 - 4.14 (m, 1H, 
H3’), 4.28 (dd, J = 11.1, 6.2 Hz, 1H, H2’), 5.03 (t, J = 5.4 Hz, 1H, OH-5’), 5.12 (d, J = 4.7 Hz, 1H, OH-
2’), 5.34 (d, J = 6.4 Hz, 1H, OH-3’), 5.99 (d, J = 6.2 Hz, 1H, H-1’), 7.57 (s, 1H, H-6), 7.93 (s, 1H, H-
2), 12.06 (br. s., 1H, NH). Spectral data are in accordance with literature values.34 
4-Oxo-5-trifluoromethyl-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (15) 53 (0.10 g,  0.15 
mmol, 1.0 eq.) was dissolved in CH2Cl2 (1 mL). MeOH (4 mL) was added, followed by NaOMe (5.4 M 
in MeOH, 0.4 mL). After 1 h, TLC analysis indicated completion of the reaction. The reaction was 
neutralized to pH 7 via the addition of 4M aq. HCl. Celite® (2 g) was added and the mixture was 
concentrated in vacuo. The residue was purified via flash column chromatography (0 → 1% 
MeOH/DCM) and the resulting product was dissolved in MeCN (3 mL). NaI (0.11 g, 0.75 mmol, 5.0 
eq.) was added, followed by TMS-Cl (0.095 mL, 0.75 mmol, 5.0 eq.). The reaction was stirred for 3 
hours at room temperature, neutralized via the addition of aq. sat. NaHCO3 (1 mL), and diluted with 
MeOH. Celite® (2 g) was added, and the mixture was concentrated in vacuo. The residue was purified 
by flash column chromatography (0 → 20% MeOH/DCM) to afford 15 as a white solid (0.040 g, 0.12 
mmol) in 80% yield. 1H NMR (300 MHz, DMSO-d6) δ 3.48 - 3.74 (m, 2H, H-5’, H-5’’), 3.92 (dd, J = 
7.0, 3.5 Hz, 1H, H-4’), 4.09 (br. s., 1H, H-3’), 4.34 (dd, J = 10.3, 4.7 Hz, 1H, H-2’), 5.10 (t, J = 5.1 Hz, 
1H, OH-5’), 5.16 (br. s., 1H, OH-2’), 5.43 (d, J = 5.3 Hz, 1H, OH-3’), 6.05 (d, J = 5.9 Hz, 1H, H-1’), 
8.04 (d, J = 1.2 Hz, 1H, H-6), 8.05 (s, 1H, H-2), 12.19 (br. s, 1H, NH). 19F NMR (282 MHz, DMSO-d6) 
δ -55.72. 13C NMR (75 MHz, DMSO-d6) δ 61.1 (C-5’), 70.2 (C-3’), 74.5 (C-2’), 85.4 (C-4’), 87.2 (C-
1’), 104.4 (C-4a), 107.9 (q, J = 38 Hz, C-5), 122.5 (q, J = 5.8 Hz, C-6), 123.4 (q, J = 266 Hz, CF3), 146.0 
(C-2), 148.9 (C-7a), 156.4 (C-4) ppm. HRMS (ESI): calculated for C12H13F3N3O5 ([M+H]+): 336.0802, 
found: 336.0813. 
4-Oxo-5-phenyl-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (16)35 26 (0.031 g, 0.090 mmol, 
1.0 eq.) was dissolved in MeCN (3 mL). NaI (0.065 g, 0.43 mmol, 5.0 eq.) was added, followed by 
TMSCl (0.055 mL, 0.43 mmol, 5.0 eq.). The reaction was stirred for 4 h at room temperature, neutralized 
via the addition of aq. sat. NaHCO3 (1 mL), and diluted with MeOH. Celite ® (2 g) was added, and the 
mixture was concentrated in vacuo. The residue was purified by flash column chromatography (0 → 20% 
MeOH/DCM) to afford 16 as a white solid (0.017 g, 0.050 mmol) in 58% yield. 1H NMR (300 MHz, 
DMSO-d6) δ 3.49 - 3.71 (m, 2H, H-5’, H-5’’), 3.90 (dd, J = 7.0, 3.5 Hz, 1H, H-4’), 4.10 (dd, J = 8.5, 4.7 
Hz, 1H, H-3’), 4.37 (dd, J = 11.4, 5.9 Hz, 1H, H-2’), 5.04 (t, J = 5.6 Hz, 1H, OH-5’), 5.13 (d, J = 5.0 
Hz, 1H, OH-2’), 5.36 (d, J = 6.2 Hz, 1H, OH-3’), 6.10 (d, J = 5.9 Hz, 1H, H-1’), 7.18 - 7.27 (m, 1H, 
HPhe), 7.29 - 7.42 (m, 2H, HPhe), 7.71 (s, 1H, H-6), 7.86 - 7.93 (m,2H, HPhe), 7.95 (s, 1H, H-2), 11.97 (br. 
s, 1H, NH) ppm. Spectral data are in accordance with literature values.35  
2-Methyl-4-oxo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (17) NaNO2 (0.069 g, 1.0 mmol, 
10.0 eq.) was added to a solution of 60 (0.028 g, 0.10 mmol, 1.0 eq.) in H2O (4 mL) and AcOH (1 mL). 
After stirring for 10 days, the mixture was concentrated in vacuo and co-evaporated with toluene three 
times. The residue was dissolved in MeOH, adsorbed onto Celite® and purified via flash column 
chromatography (0 → 20% MeOH/DCM) to afford 17 as a white solid (0.018 g, 0.060 mmol, 64% 
yield). 1H NMR (300 MHz, DMSO-d6) δ ppm 2.33 (s, 3H, CH3), 3.43 - 3.70 (m, 2H, H-5’, H-5’’), 3.87 
(dd, J = 7.0, 3.8 Hz, 1H, H-4’), 4.07 (m, 1H, H-3’), 4.34 (dd, J = 11.1, 5.6 Hz, 1H, H-2’), 5.06 (t, J = 
5.4 Hz, 1H, OH-5’), 5.10 - 5.15 (m, 1H, OH-2’), 5.27 (d, J = 6.2 Hz, 1H, OH-3’), 5.97 (d, J = 6.4 Hz, 
1H, H-1’), 6.46 (d, J = 3.5 Hz, 1H, H-5), 7.26 (d, J = 3.5 Hz, 1H, H-6), 11.88 (br. s., 1H, NH). 13C NMR 
(75 MHz, DMSO-d6) δ 20.9 (CH3), 61.7 (C-5’), 70.7 (C-3’), 74.0 (C-2’), 85.1 (C-4’), 86.8 (C-1’), 102.1 
(C-5), 106.0 (C-4a), 120.6 (C-6), 148.3 (C-7a), 153.0 (C-2), 158.9 (C-4). HRMS (ESI): calculated for 
C12H16N3O5 ([M+H]+): 282.1085, found: 282.1078. 
2-Amino-4-oxo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (18)44 A solution of 20 (0.11 g, 
0.35 mmol, 1.0 eq.) in 0.5 N NaOH (8 mL) was refluxed for 2 hours. After cooling to room temperature, 
the reaction was neutralized to pH 7 via the addition of 4M aq. HCl. The mixture was concentrated in 
vacuo and the residue taken up in MeOH, adsorbed onto Celite® and purified by flash column 
chromatography (20% MeOH/DCM and 40% MeOH/DCM) to afford 18 as a white solid (0.043 g, 0.15 
mmol) in 44% yield. 1H NMR (300 MHz, DMSO-d6) δ 3.41 - 3.62 (m,2H, H-5’, H-5’’), 3.80 (dd, J = 
7.6, 3.8 Hz, 1H, H-4’), 4.02 (dd, J = 8.5, 4.4 Hz, 1H, H-3’), 4.23 (dd, J = 11.7, 5.9 Hz, 1H, H-2’), 4.96 
(t, J = 5.6 Hz, 1H, OH-5’), 5.03 (d, J = 4.4 Hz, 1H, OH-2’), 5.22 (d, J = 6.2 Hz, 1H, OH-3’), 5.86 (d, J 
= 6.2 Hz, 1H, H-1’), 6.26 (d, J = 4.1 Hz, 1H, H-5), 6.30 (br. s, 2H, NH2), 6.92 (d, J = 3.5 Hz, 1H, H-6), 
10.42 (s, 1H, NH). Spectral data are in accordance with literature values.44 
2-Amino-4-oxo-5-bromo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (19)43 28 (0.054 g, 0.14 
mmol) was suspended in 1,4-dioxane (2.0 mL, 13.3 mL/mmol SM). Next, 2M aq. NaOH sol. (13 mL, 
89 mL/mmol SM) was added and the mixture heated till reflux for 4 h. after cooling to ambient 
temperature, the mixture was neutralized by concentrated HCl and evaporated. The residue was purified 
by column chromatography 15 → 22 % MeOH/CHCl3 to give, after precipitation from water, 19 (0.028 
g, 0.078 mmol) as a yellowish solid in 54 % yield. 1H NMR (300 MHz, DMSO-d6) δ: 3.45 – 3.59 (m, 
2H, H-5’, H-5’’), 3.80 (dd, J = 7.2, 3.9 Hz, 1H, H-4’), 4.00 – 4.04 (m, 1H, H-3’), 4.20 (dd, J = 11.4, 6.3 
Hz, 1H, H-2’), 5.01 (t, J = 5.4 Hz, 1H, OH-5’), 5.10 (d, J = 4.5 Hz, 1H, OH-3’), 5.30 (d, J = 6.3 Hz, 1H, 
OH-2’), 5.85 (d, J = 6.3 Hz, 1H, H-1’), 6.65 (br. s, 2H, NH2), 7.08 (s, 1H, H-6), 10.73 (br. s, 1H, NH). 
HRMS (ESI): calculated for C11H12BrN4O5 ([M-H]-): 358.9997, found: 358.9935. Spectral data are in 
accordance with literature values.43 
2-Amino-4-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (20)44 56 (0.40 g, 0.87 mmol, 
1.0 eq.) is dissolved in TFA (4.5 mL). H2O (0.5 mL) was added, and the mixture was stirred for 2 h at 
room temperature. The mixture was concentrated in vacuo and co-evaporated three times with toluene 
to remove all TFA. The residue was taken up in MeOH, adsorbed onto Celite® and purified by flash 
column chromatography (0 → 10% MeOH/DCM). The residue was then lyophilized to afford 20 as a 
white solid (0.13 g, 0.42 mmol) in 48 % yield. 1H NMR (300 MHz, DMSO-d6) δ 3.52 (dd, J = 11.7, 4.1 
Hz, 1H, H-5’), 3.56 (dd, J = 12.0, 4.1 Hz, 1H, H-5’’), 3.84 (dd, J = 7.3, 4.1 Hz, 1H, H-4’), 4.04 (dd, J = 
5.0, 3.2 Hz, 1H, H-3’), 4.30 (t, J = 5.7 Hz, 1H, H-2’), 4.79 - 5.51 (m, 3H, OH-2’, OH-3’, OH-5’), 5.98 
(d, J = 6.2 Hz, 1H, H-1’), 6.36 (d, J = 3.5 Hz, 1H, H-5), 6.68 (br. s., 2H, NH2), 7.37 (d, J = 4.1 Hz, 1H, 
H-6). Spectral data are in accordance with literature values.44 
2-Amino-5-bromo-4-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (21)43  57 (0.26 g, 
0.48 mmol, 1.0 eq.) is dissolved in TFA (4.5 mL). H2O (0.5 mL) was added, and the mixture was stirred 
for 1 h at room temperature. The mixture was concentrated in vacuo and co-evaporated three times with 
toluene to remove all TFA. The residue was taken up in MeOH, adsorbed onto Celite® and purified by 
flash column chromatography (2 → 12% MeOH/DCM). The residue was then lyophilized to afford 21 
as a white solid (0.11 g, 0.28 mmol) in 59% yield. 1H NMR (300 MHz, DMSO-d6) δ 3.46 - 3.73 (m, 2H, 
H-5’, H-5’’), 3.85 (dd, J = 7.3, 4.1 Hz, 1H, H-4’), 4.05 (dd, J = 7.6, 3.8 Hz, 1H, H-3’), 4.29 (dd, J = 
11.7, 5.9 Hz, 1H, H-2’), 5.01 (t, J = 5.3 Hz, 1H, OH-5’), 5.10 (d, J = 4.4 Hz, 1H, OH-2’), 5.33 (d, J = 
5.9 Hz, 1H, OH-3’), 6.00 (d, J = 6.4 Hz, 1H, H-1’), 6.92 (br. s, 2H, NH2), 7.61 (s, 1H, H-6). Spectral 
data are in accordance with literature values.43  
2-Amino-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (22)59 20 (0.064 g, 0.21 mmol, 1.0 eq.) 
was dissolved in MeOH (10 mL) and NH4OH (0.5 mL) was added. Next, the flask was purged with N2, 
after which a cat. amount of Pd/C was added. Next, the N2-atmosphere was exchanged for H2 (balloon; 
no bubbling) and the mixture stirred for 4 hours. The mixture was filtered over Celite®, and the filtrate 
concentrated in vacuo. The residue was dissolved in MeOH, adsorbed onto Celite® and purified by flash 
column chromatography (0 → 30% MeOH/DCM) to afford 22 as a white solid (0.016 g, 0.060 mmol, 
28% yield). 1H NMR (300 MHz, DMSO-d6):  3.43 - 3.73 (m, 2H, H-5’, H-5’’), 3.84 (dd, J = 7.3, 4.1 
Hz, 1H, H-4’), 3.95 - 4.14 (m, 1H, H-3’), 4.33 (br. s., 1H, H-2’), 4.99 (br. s., 1H, OH-5’), 5.08 (br. s., 
1H, OH-2’), 5.26 (br. s., 1H, OH-3’), 6.02 (d, J = 6.4 Hz, 1H, H-1’), 6.23 (s,2H, NH2), 6.37 (d, J = 3.8 
Hz, 1H, H-5), 7.28 (d, J = 3.8 Hz, 1H, H-6), 8.46 (s, 1H, H-4) ppm. Spectral data are in accordance with 
literature values.59 
4-Methoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (23)34 4834 (0.32 g, 0.5. 
mmol, 1 eq.) was suspended in MeOH (12 mL) and 5.4 M NaOMe/MeOH (1 mL) was added. The 
resulting mixture was heated at 50 °C for 2 h, after which LC/MS analysis showed full conversion of 
the starting material. Next, the mixture was neutralized with c.HCl solution and evaporated till dryness. 
The residue was purified by column chromatography 0 → 10 % MeOH/EA to give 23 (0.10 g, 0.28 
mmol) as a white solid in 57 % yield. Melting point: 171 °C. 1H NMR (300 MHz, DMSO-d6) δ: 3.54 
(ddd, J = 12.0, 5.7, 3.9, 1H, H-5’’), 3.63 (ddd, J = 12.0, 5.1, 3.9 Hz, 1H, H-5’), 3.91 (q, J = 3.9 Hz, 1H, 
H-4’), 4.07 (s, 3H, OCH3), 4.05 – 4.11 (m, 1H, H-3’), 4.36 (dd, J = 11.4, 6.0 Hz, 1H, H-2’), 5.07 (t, J = 
5.4 Hz, 1H, OH-5’), 5.16 (d, J = 4.8 Hz, 1H, OH-3’), 5.38 (d, J = 6.3 Hz, 1H, OH-2’), 6.16 (d, J = 6.0 
Hz, 1H, H-1’), 7.85 (s, 1H, H-6), 8.47 (s, 1H, H-2). Spectral data are in accordance with literature 
values.34 
4-Methoxy-5-bromo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (24)34 4934 (0.25 g, 0.37 
mmol, 1 eq.) was suspended in 0.5 M NaOMe/MeOH (7.5 mL). The resulting mixture was heated at 
50 °C for 3 h, after which LC/MS analysis showed full conversion of the starting material. Next, the 
mixture was neutralized with c.HCl solution and evaporated till dryness. The residue was purified by 
column chromatography 0 → 5 % MeOH/DCM to give 24 (0.090 g, 0.25 mmol) as a white solid in 67 % 
yield. 1H NMR (300 MHz, DMSO-d6) δ: 3.54 (ddd, J = 12.0, 5.7, 3.9 Hz, 1H, H-5’’), 3.64 (ddd, J = 
12.0, 5.4, 4.2 Hz, 1H, H-5’), 3.91 (q, J = 3.9 Hz, 1H, H-4’), 4.05 (s, 3H, OCH3), 4.06 – 4.11 (m, 1H, H-
3’), 4.34 – 4.39 (m, 1H, H-2’), 5.08 (t, J = 5.7 Hz, 1H, OH-5’), 5.16 (d, J = 4.8 Hz, 1H, OH-3’), 5.38 (d, 
J = 6.3 Hz, 1H, OH-2’), 6.16 (d, J = 6.3 Hz, 1H, H-1’), 7.88 (s, 1H, H-6), 8.46 (s, 1H, H-2). Spectral 
data are in accordance with literature values.34 
4-Methoxy-5-iodo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (25)34 NaOMe (5.4 M in 
MeOH, 1 mL) was added to 5034 (0.56 g, 0.77 mmol, 1.0 eq.) in MeOH (10 mL). After 3 hours, the 
reaction mixture was neutralized with 4 M HCl to pH 7. Celite® (2g)  was added, the mixture was 
concentrated in vacuo, and the residue purified by flash column chromatography (0 → 6% MeOH/DCM) 
to afford 25 as a white solid (0.17 g, 0.42 mmol) in 54% yield. 1H NMR (300 MHz, DMSO-d6) δ 3.59 
(m, 2H, 5-H’, 5-H’’), 3.90 (dd, J = 6.4, 3.2 Hz, 1H, H-4’), 4.00 - 4.17 (m, 4H, OCH3 + H-3’), 4.37 (dd, 
J = 11.7, 5.9 Hz, 1H, H-2’), 5.08 (t, J = 5.4 Hz, 1H, OH-5’), 5.15 (d, J = 4.7 Hz, 1H, OH-2’), 5.35 (d, J 
= 6.2 Hz, 1H, OH-3’), 6.13 (d, J = 6.2 Hz, 1H, H-1’), 7.88 (s,1H, H-5), 8.44 (s, 1H, H-6). Spectral data 
are in accordance with literature values.34 
4-Methoxy-5-phenyl-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (26)35 25 (0.060 g, 0.15 
mmol, 1.0 eq.), phenylboronic acid (0.027 g, 0.22 mmol, 1.5 eq.), Na2CO3 (0.047 g, 0.44 mmol, 3.0 eq.), 
Pd(OAc)2 (0.002 g, 0.007 mmol, 0.05 eq.) and TPPTS (0.010 g, 0.018 mmol, 0.12 eq.) were added to a 
10 mL round-bottom flask equipped with a stir bar. Next, the flask was evacuated and refilled with argon. 
This procedure was repeated three times in total. Next, degassed MeCN (1 mL) and H2O (2 mL) were 
added to the solids under argon. After 5 min of stirring, the mixture was heated to 100 °C on a pre-
heated heating block. After 1 hour, the mixture was cooled to ambient temperature, and neutralized (pH 
~ 7) with 1 M aq. HCl. Celite® (2 g) was added, the mixture concentrated in vacuo, and the residue 
purified by flash column chromatography (0 → 12% MeOH/DCM) to afford 26 as a white solid (0.048 
g, 0.13 mmol) in 91% yield. 1H NMR (300 MHz, CD3OD-d4) δ 3.76 (dd, J = 12.3, 3.2 Hz, 1H, H-5’), 
3.88 (dd, J = 12.2, 2.8 Hz, 1H, H-5’’), 4.07 (3H, s, OCH3), 4.13 (dd, J = 6.2, 2.9 Hz, 1H, H-4’), 4.33 
(dd, J = 5.4, 3.4 Hz, 1H, H-3’), 4.65 (t, J = 5.7 Hz, 1H, H-2’), 6.22 (d, J = 6.2 Hz, 1H, H-1’), 7.20 - 7.34 
(m, 1H, HPhe), 7.34 - 7.46 (m, 2H, HPhe), 7.55 - 7.75 (m, 3H, 2HPhe & H-6), 8.40 (s, 1H, H-2). Spectral 
data are in accordance with literature values.35 
4-Methoxy-5-(4-chlorophenyl)-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (27) 25 (0.060 g, 
0.15 mmol, 1.0 eq.), 4-chlorophenylboronic acid (0.035 g, 0.22 mmol, 1.5 eq.), Na2CO3 (0.047 g, 0.44 
mmol, 3.0 eq.), Pd(OAc)2 (0.002 g, 0.007 mmol, 0.05 eq.) and TPPTS (0.010 g, 0.018 mmol, 0.12 eq.) 
were added to a 10 mL round-bottom flask, equipped with a stir bar. Next, the flask was evacuated and 
refilled with argon. This procedure was repeated three times in total. Next, degassed MeCN (1 mL) and 
H2O (2 mL) were added to the solids under argon. After 5 min of stirring, the mixture was heated to 
100 °C on a pre-heated heating block. After 1 hour, the mixture was cooled to ambient temperature, and 
neutralized (pH ~ 7) with 1 M aq. HCl. Celite® (2 g) was added, the mixture concentrated in vacuo, and 
the residue purified by flash column chromatography (0→12% MeOH/DCM) to afford 27 as a white 
solid (0.019 g, 0.050 mmol) in 33% yield. 1H NMR (300 MHz, CD3OD-d4) δ 3.76 (dd, J = 12.3, 3.2 Hz, 
1H, H-5’), 3.88 (dd, J = 12.3, 2.9 Hz, 1H, H-5’’), 4.07 (s, 3H, OCH3), 4.13 (dd, J = 6.2, 2.9 Hz, 1H, H-
4’), 4.32 (dd, J = 5.3, 3.2 Hz, 1H, H-3’), 4.64 (t, J = 5.7 Hz, 1H, H-2’), 6.21 (d, J = 6.2 Hz, 1H, H-1’), 
7.31 - 7.44 (m, 2H, HPhe), 7.59 - 7.67 (m, 2H, HPhe), 7.69 (s, 1H, H-6), 8.40 (s, 1H, H-2). 13C NMR (75 
MHz, CD3OD-d4) δ 54.4 (OCH3), 63.4 (C-5’), 72.5 (C-3’), 75.9 (C-2’), 87.2 (C-4’), 90.8 (C-1’), 105.5 
(C-6), 124.6 (CPhe), 129.3 (CPhe), 131.5 (CPhe), 133.7 (CPhe), 152.0 (C-2), 165.0 (C-4) ppm. Three 
quaternary carbons could not be detected (C-5, C-4a, C-7a). HRMS (ESI): calculated for C18H19ClN3O5 
([M+H]+): 392.1008, found: 392.1000. 
2-Amino-4-methoxy-5-bromo-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (28)43 54 (1.0 g, 
1.3 mmol, 1 eq.) was dissolved in 0.5 M NaOMe/MeOH sol. and heated to reflux for 3 h. After cooling 
to ambient temperature, the mixture was neutralized with 3 M aq. HCl sol. and evaporated till dryness. 
The residue was purified by column chromatography 2.5 → 5 % MeOH/DCM to give 28 (0.27 g, 0.72 
mmol) as a yellow solid in 56 % yield. 1H NMR (300 MHz, DMSO-d6) δ: 3.50 (ddd, J = 12.0, 5.4, 4.2 
Hz, 1H, H-5’’), 3.58 (ddd, J = 12.0, 5.4, 4.2 Hz, 1H, H-5’), 3.82 (dd, J = 7.2, 4.2 Hz, 1H, H-4’), 3.93 (s, 
3H, OCH3), 4.01 – 4.05 (m, 1H, H-3’), 4.26 (dd, J = 11.7, 6.3 Hz, 1H, H-2’), 4.99 (t, J = 5.4 Hz, 1H, 
OH-5’), 5.05 (d, J = 4.5 Hz, 1H, OH-3’), 5.26 (d, J = 6.0 Hz, 1H, OH-2’), 5.97 (d, J = 6.6 Hz, 1H, H-
1’), 6.42 (br. s, 2H, NH2), 7.29 (s, 1H, H-6). HRMS (ESI): calculated for C12H16BrN4O5 ([M+H]+): 
375.0299, found: 375.0304. Spectral data are in accordance with literature values.43 
4-Ethoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (29) 48 (0.19 g, 0.30 mmol, 1 
eq.) was suspended in EtOH (6.9 mL) and 20 % (W/V) NaOEt/EtOH (0.10 mL) was added. The resulting 
mixture was heated at 50 °C for 2 h, after which LC/MS analysis showed full conversion of the starting 
material. Next, the mixture was neutralized with concentrated HCl solution and evaporated till dryness. 
The residue was purified by column chromatography 0 → 10 % MeOH/DCM to give 29 (0.020 g, 0.061 
mmol) as a white solid in 20 % yield. Melting point: 140 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.39 (t, 
J = 6.9 Hz, 3H, CH3), 3.54 (ddd, J = 12.0, 5.7, 3.9 Hz, 1H, H-5’’), 3.63 (ddd, J = 12.0, 5.1, 4.2 Hz, 1H, 
H-5’), 3.91 (q, J = 3.6 Hz, 1H, H-4’), 4.07 – 4.11 (m, 1H, H-3’), 4.32 – 4.38 (m, 1H, H-2’), 4.55 (q, J = 
6.9 Hz, 2H, OCH2), 5.07 (t, J = 5.7 Hz, 1H, OH-5’), 5.16 (d, J = 4.8 Hz, 1H, OH-3’), 5.37 (d, J = 6.3 
Hz, 1H, OH-2’), 6.15 (d, J = 6.3 Hz, 1H, H-1’), 7.83 (s, 1H, H-6), 8.44 (s, 1H, H-2). 13C NMR (75 MHz, 
DMSO-d6) δ: 14.3 (CH3), 61.4 (C-5’), 62.2 (OCH2), 70.4 (C-3’), 74.1 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 
102.7, 102.8, 121.7 (C-6), 150.6 (C-7a), 151.6 (C-2), 161.9 (C-4). HRMS (ESI): calculated for 
C13H17ClN3O5 ([M+H]+): 330.0851, found: 330.0774. 
4-Propoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (30) 48 (0.19 g, 0.30 mmol, 
1 eq.) was suspended in 0.5 M NaOPr/nPrOH solution (7.0 mL) [Na0 wire (0.12 g) was added to nPrOH 
(10 mL) under argon and stirred vigorously until the wire was fully dissolved]. The resulting mixture 
was heated at 50 °C for 3 h, after which LC/MS analysis showed full conversion of the starting material. 
Next, the mixture was neutralized with concentrated HCl solution and evaporated till dryness. The 
residue was purified by column chromatography 0 → 8 % MeOH/DCM to give 30 (0.040 g, 0.12 mmol) 
as a white solid in 39 % yield. Melting point: 134 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.02 (t, J = 7.5 
Hz, 3H, CH3), 1.74 – 1.85 (m, 2H, CH2), 3.51 – 3.58 (m, 1H, H-5’’), 3.60 – 3.67 (m, 1H, H-5’), 3.91 (q, 
J = 3.9 Hz, 1H, H-4’), 4.09 (br. s, 1H, H-3’), 4.35 (br. s, 1H, H-2’), 4.46 (t, J = 6.3 Hz, 2H, OCH2), 5.08 
(t, J = 5.4 Hz, 1H, OH-5’), 5.17 (br. s, 1H, OH-3’), 5.38 (br. s, 1H, OH-2’), 6.15 (d, J = 6.3 Hz, 1H, H-
1’), 7.83 (s, 1H, H-6), 8.43 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 10.3 (CH3), 21.7 (CH2), 61.4 
(C-5’), 67.7 (OCH2), 70.4 (C-3’), 74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.7, 102.8, 121.7 (C-6), 150.6 
(C-7a), 151.7 (C-2), 162.1 (C-4). HRMS (ESI): calculated for C14H19ClN3O5 ([M+H]+): 344.1008, found: 
344.0921. 
4-Butoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (31) 48 (0.19 g, 0.30 mmol, 1 
eq.) was suspended in 0.5 M NaOBu/nBuOH solution (7.0 mL) [Na0 wire (0.12 g) was added to nBuOH 
(10 mL) under argon and stirred vigorously until the wire was fully dissolved]. The resulting mixture 
was heated at 50 °C for 3 h, after which LC/MS analysis showed full conversion of the starting material. 
Next, the mixture was neutralized with concentrated HCl solution and evaporated till dryness. The 
residue was purified by column chromatography 0 → 8 % MeOH/DCM to give 31 (0.065 g, 0.18 mmol) 
as a white solid in 61 % yield. Melting point: 156 °C. 1H NMR (300 MHz, DMSO-d6) δ: 0.95 (t, J = 7.5 
Hz, 3H, CH3), 1.42 – 1.54 (m, 2H, OCH2CH2CH2), 1.72 – 1.81 (m, 2H, OCH2CH2CH2), 3.54 (ddd, J = 
12.0, 5.7, 4.2 Hz, 1H, H-5’’), 3.64 (ddd, J = 12.0, 5.4, 4.2 Hz, 1H, H-5’), 3.91 (q, J = 3.9 Hz, 1H, H-4’), 
4.09 (dd, J = 8.1, 4.5 Hz, 1H, H-3’), 4.35 (dd, J = 11.0, 6.0 Hz, 1H, H-2’), 4.50 (t, J = 6.6 Hz, 2H, OCH2), 
5.08 (t, J = 5.4 Hz, 1H, OH-5’), 5.16 (d, J = 4.8 Hz, 1H, OH-3’), 5.37 (d, J = 6.0 Hz, 1H, OH-2’), 6.15 
(d, J = 6.3 Hz, 1H, H-1’), 7.83 (s, 1H, H-6), 8.43 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 13.6 
(CH3), 18.7 (OCH2CH2CH2), 30.3 (OCH2CH2CH2), 61.4 (C-5’), 65.9 (OCH2), 70.4 (C-3’), 74.2 (C-2’), 
85.3 (C-4’), 86.8 (C-1’), 102.7, 102.8, 121.6 (C-6), 150.6 (C-7a), 151.6 (C-2), 162.0 (C-4). HRMS (ESI): 
calculated for C14H19ClN3O5 ([M+H]+): 358.1164, found: 358.1164. 
4-Pentoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (32) n-Pentanol (4.0 mL) was 
added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert atmosphere. Then, 48 (0.19 g, 
0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 2 – 3 h. After cooling to 
ambient temperature, the mixture was neutralized with 1 M aq. HCl solution and evaporated till dryness. 
The residue was adsorbed onto Celite® from MeOH solution and purified by column chromatography 
0.5 → 6 % MeOH/DCM to give 32 (0.065 g, 0.18 mmol) as a white solid in 59 % yield. Melting point: 
140 °C. 1H NMR (300 MHz, DMSO-d6) δ: 0.89 (t, J = 7.2 Hz, 3H, CH3), 1.30 – 1.49 (m, 4H, CH2), 1.74 
– 1.83 (m, 2H, CH2), 3.54 (ddd, J = 12.0, 5.4, 3.9 Hz, 1H, H-5’’), 3.63 (ddd, J = 12.0, 5.1, 4.2 Hz, 1H, 
H-5’), 3.91 (q, J = 3.6 Hz, 1H, H-4’), 4.07 – 4.11 (m, 1H, H-3’), 4.35 (q, J = 5.7 Hz, 1H, H-2’), 4.50 (t, 
J = 6.9 Hz, 2H, OCH2), 5.08 (t, J = 5.4 Hz, 1H, OH-5’), 5.17 (d, J = 4.5 Hz, 1H, OH-3’), 5.38 (d, J = 
6.3 Hz, 1H, OH-2’), 6.15 (d, J = 6.0 Hz, 1H, H-1’), 7.83 (s, 1H, H-6), 8.43 (s, 1H, H-2). 13C NMR (75 
MHz, DMSO-d6) δ: 13.9 (CH3), 21.8 (CH2), 27.6 (CH2), 27.9 (CH2), 61.4 (C-5’), 68.2 (OCH2), 70.4 (C-
3’), 74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.7, 102.8, 121.7 (C-6), 150.6 (C-7a), 151.6 (C-2), 162.0 
(C-4). HRMS (ESI): calculated for C16H23ClN3O5 ([M+H]+): 372.1321, found: 372.1313. 
4-Phenethoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (33) 2-Phenylethanol 
(4.0 mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert atmosphere. Then, 
48 (0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 2 – 3h. After 
cooling to ambient temperature, the mixture was neutralized with 1 M aq. HCl solution and evaporated 
till dryness. The residue was adsorbed onto Celite® from MeOH solution and purified by column 
chromatography 0.5 → 6 % MeOH/DCM to give 33 (0.10 g, 0.25 mmol) as a white solid in 84 % yield. 
Melting point: 154 °C. 1H NMR (300 MHz, DMSO-d6) δ: 3.10 (t, J = 6.6 Hz, 2H, PhCH2), 3.51 – 3.58 
(m, 1H, H-5’’), 3.63 (ddd, J = 12.0, 5.4, 4.5 Hz, 1H, H-5’), 3.90 (q, J = 3.6 Hz, 1H, H-4’), 4.06 – 4.11 
(m, 1H, H-3’), 4.34 (q, J = 5.4 Hz, 1H, H-2’), 4.69 (t, J = 6.6 Hz, 1H, OCH2), 5.07 (t, J = 5.4 Hz, 1H, 
OH-5’), 5.16 (d, J = 4.8 Hz, 1H, OH-3’), 5.37 (d, J = 6.0 Hz, 1H, OH-2’), 6.14 (d, J = 6.0 Hz, 1H, H-
1’), 7.18 – 7.38 (m, 5H, HPhe), 7.83 (s, 1H, H-6), 8.44 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 
34.6 (CH2), 61.4 (C-5’), 67.0 (OCH2), 70.4 (C-3’), 74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.66, 102.75, 
121.8 (C-6), 126.3 (CPhe), 128.3 (2C, CPhe), 129.1 (2C, CPhe), 138.3 (CPhe), 150.6 (C-7a), 151.6 (C-2), 
161.8 (C-4). HRMS (ESI): calculated for C19H21ClN3O5 ([M+H]+): 406.1164, found: 406.1164. 
4-(2-Methoxyethoxy)-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (34) 2-
Methoxyethanol (4.0 mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert 
atmosphere. Then, 48 (0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 
2 – 3 h. After cooling to ambient temperature, the mixture was neutralized with 1 M aq. HCl solution 
and evaporated till dryness. The residue was adsorbed onto Celite® from MeOH solution and purified 
by column chromatography 0.5 → 6 % MeOH/DCM to give 34 (0.055 g, 0.15 mmol) as a white solid 
in 51 % yield. Melting point: 155 °C. 1H NMR (300 MHz, DMSO-d6) δ: 3.33 (s, 3H, OCH3), 3.55 (ddd, 
J = 12.0, 5.4, 4.2 Hz, 1H, H-5’’), 3.64 (ddd, J = 12.0, 5.1, 3.9 Hz, 1H, H-5’), 3.72 – 3.76 (m, 2H, OCH2), 
3.91 (q, J = 3.6 Hz, 1H, H-4’), 4.07 – 4.11 (m, 1H, H-3’), 4.35 (q, J = 5.7 Hz, 1H, H-2’), 4.62 – 4.65 (m, 
2H, OCH2), 5.08 (t, J = 5.4 Hz, 1H, OH-5’), 5.17 (d, J = 4.8 Hz, 1H, OH-3’), 5.38 (d, J = 6.3 Hz, 1H, 
OH-2’), 6.16 (d, J = 6.3 Hz, 1H, H-1’), 7.85 (s, 1H, H-6), 8.44 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-
d6) δ: 58.4, 61.4 (C-5’), 65.7, 70.0, 70.4 (C-3’), 74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.7, 102.8, 121.8 
(C-6), 150.7 (C-7a), 151.7 (C-2), 161.8 (C-4). HRMS (ESI): calculated for C14H19ClN3O6 ([M+H]+): 
360.0957, found: 360.0976. 
4-(2-Phenoxyethoxy)-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (35) 2-
Phenoxyethanol (4.0 mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert 
atmosphere. Then, 48 (0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 
2 – 3 h. After cooling to ambient temperature, the mixture was neutralized with 1 M aq. HCl solution 
and evaporated till dryness. The residue was adsorbed onto Celite® from MeOH solution and purified 
by column chromatography 0.5 → 6 % MeOH/DCM to give 35 (0.060 g, 0.14 mmol) as a white solid 
in 84 % yield. Melting point: 115 °C. 1H NMR (300 MHz, DMSO-d6) δ: 3.54 (ddd, J = 12.0, 5.7, 3.9 
Hz, 1H, H-5’’), 3.64 (ddd, J = 12.0, 5.4, 4.2 Hz, 1H, H-5’), 3.91 (q, J = 3.6 Hz, 1H, H-4’), 4.07 – 4.11 
(m, 1H, H-3’), 4.35 (q, J = 6.0 Hz, 1H, H-2’), 4.38 – 4.41 (m, 2H, PhOCH2), 4.83 – 4.86 (m, 2H, OCH2), 
5.08 (t, J = 5.4 Hz, 1H, OH-5’), 5.17 (d, J = 4.8 Hz, 1H, OH-3’), 5.38 (d, J = 6.3 Hz, 1H, OH-5’), 6.16 
(d, J = 6.3 Hz, 1H, H-1’), 6.91 – 7.01 (m, 3H, HPhe), 7.25 – 7.32 (m, 2H, HPhe), 7.85 (s, 1H, H-6), 8.47 
(s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 61.3 (C-5’), 64.9 (OCH2), 65.9 (OCH2), 70.4 (C-3’), 
74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.7, 102.8, 114.6 (2C, CPhe), 120.8 (CPhe), 121.9 (C-6), 129.5 
(2C, CPhe), 150.7 (C-7a), 151.5 (C-2), 158.3 (CPhe), 161.7 (C-4). HRMS (ESI): calculated for 
C19H21ClN3O6 ([M+H]+): 422.1113, found: 422.1136. 
4-Isopropoxy-5-chloro-(N7-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (36) 48 (0.19 g, 0.30 
mmol, 1 eq.) was suspended in 0.5 M Na-iOPr/iPrOH solution (7.0 mL). [Na0 wire (0.12 g) was added 
to iPrOH (10 mL) under argon and stirred vigorously until the wire was fully dissolved] The resulting 
mixture was heated at 50 °C for 3 h, after which LC/MS analysis showed full conversion of the starting 
material. Next, the mixture was neutralized with concentrated HCl solution and evaporated till dryness. 
The residue was purified by column chromatography 0 → 8 % MeOH/DCM to give 36 (0.037 g, 0.11 
mmol) as a white solid in 36 % yield. Melting point: 127 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.38 
(dd, J = 6.3, 2.1 Hz, 6H, 2 x CH3), 3.54 (ddd, J = 12.0, 5.7, 3.9 Hz, 1H, H-5’’), 3.63 (ddd, J = 12.0, 5.1, 
4.2 Hz, 1H, H-5’), 3.90 (q, J = 3.9 Hz, 1H, H-4’), 4.09 (dd, J = 8.1, 4.8 Hz, 1H, H-3’), 4.35 (dd, J = 
11.4, 6.3 Hz, 1H, H-4’), 5.08 (t, J = 5.7 Hz, 1H, OH-5’), 5.16 (d, J = 4.8 Hz, 1H, OH-3’), 5.36 (d, J = 
6.3 Hz, 1H, OH-2’), 5.52 (sept., J = 6.3 Hz, 1H, CH), 6.14 (d, J = 6.0 Hz, 1H, H-1’), 7.81 (s, 1H, H-6), 
8.42 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 21.8 (2C, CH3), 61.4 (C-5’), 69.3 (OCH2), 70.4 (C-
3’), 74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.87, 102.90, 121.6 (C-6), 150.7 (C-7a), 151.6 (C-2), 161.7 
(C-4). HRMS (ESI): calculated for C14H19ClN3O5 ([M+H]+): 344.1008, found: 344.0901. 
4-Isobutoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (37) 2-Methyl-propan-1-ol 
(4.0 mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert atmosphere. Then, 
48 (0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 2 – 3 h. After 
cooling to ambient temperature, the mixture was neutralized with 1M aq. HCl solution and evaporated 
till dryness. The residue was adsorbed onto Celite® from MeOH solution and purified by column 
chromatography 0.5 → 6 % MeOH/DCM to give 37 (0.088 g, 0.25 mmol) as a white solid in 82 % yield. 
Melting point: 184 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.02 (d, J = 6.9 Hz, 6H, CH3), 2.10 (sept., J 
= 6.6 Hz, 1H, CH), 3.53 – 3.57 (br. s, 1H, H-5’’), 3.62 – 3.66 (br. s, 1H, H-5’), 3.91 (q, J = 3.6 Hz, 1H, 
H-4’), 4.08 – 4.11 (m, 1H, H-3’), 4.29 (d, J = 6.3 Hz, 2H, OCH2), 4.35 (t, J = 5.7 Hz, 1H, H-2’), 5.08 
(br. s, 1H, OH-5’), 5.19 (br. s, 1H, OH-3’), 5.40 (br. s, 1H, OH-2’), 6.15 (d, J = 6.0 Hz, 1H, H-1’), 7.84 
(s, 1H, H-6), 8.43 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 18.9 (2C, CH3), 27.5 (CH), 61.4 (C-
5’), 70.4 (OCH2), 72.0 (C-3’), 74.2 (C-2’), 85.3 (C-4’), 86.9 (C-1’), 102.75, 102.81, 121.7 (C-6), 150.8 
(C-7a), 151.7 (C-2), 162.1 (C-4). HRMS (ESI): calculated for C15H21ClN3O5 ([M+H]+): 358.1164, found: 
358.1172. 
4-Isopentyloxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (38) Isoamylalcohol (4 
mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert atmosphere. Then, 48 
(0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 2 – 3 h. After cooling 
to ambient temperature, the mixture was neutralized with 1M aq. HCl solution and evaporated till 
dryness. The residue was adsorbed onto Celite® from MeOH solution and purified by column 
chromatography 0.5 → 6 % MeOH/DCM to give 38 (0.085 g, 0.23 mmol) as a white solid in 76 % yield. 
Melting point: 150 °C. 1H NMR (300 MHz, DMSO-d6) δ: 0.95 (d, J = 6.6 Hz, 6H, CH3), 1.68 (q, J = 
6.6 Hz, 2H, CH2), 1.83 (sept., J = 6.9 Hz, 1H, CH), 3.54 (ddd, J = 12.0, 5.7, 3.9 Hz, 1H, H-5’’), 3.63 
(ddd, J = 12.0, 5.4, 4.2 Hz, 1H, H-5’), 3.91 (q, J = 3.6 Hz, 1H, H-4’), 4.07 – 4.11 (m, 1H, H-3’), 4.35 
(q, J = 6.0 Hz, 1H, H-2’), 4.54 (t, J = 6.6 Hz, 2H, OCH2), 5.08 (t, J = 5.4 Hz, 1H, OH-5’), 5.16 (d, J = 
5.1 Hz, 1H, OH-3’), 5.37 (d, J = 6.6 Hz, 1H, OH-2’), 6.15 (d, J = 5.7 Hz, 1H, H-1’), 7.83 (s, 1H, H-6), 
8.44 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 22.4 (2C, CH3), 24.7 (CH), 37.0 (CH2), 61.4 (C-
5’), 64.7 (OCH2), 70.4 (C-3’), 74.2 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.72, 102.79, 121.7 (C-6), 150.6 
(C-7a), 151.6 (C-2), 162.0 (C-4). HRMS (ESI): calculated for C16H23ClN3O5 ([M+H]+): 372.1321, found: 
372.1314.  
4-Cyclopentoxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (39) Cyclopentanol 
(4.0 mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert atmosphere. Then, 
48 (0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 2 – 3 h. After 
cooling to ambient temperature, the mixture was neutralized with 1M aq. HCl solution and evaporated 
till dryness. The residue was adsorbed onto Celite® from MeOH solution and purified by column 
chromatography 0.5 → 6 % MeOH/DCM to give 39 (0.030 g, 0.081 mmol) as a white solid in 27 % 
yield. Melting point: 176 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.58 – 1.85 (m, 6H, CH2), 1.91 – 2.03 
(m, 2H, CH2), 3.51 – 3.57 (m, 1H, H-5’’), 3.60 – 3.66 (m, 1H, H-5’), 3.90 (q, J = 3.6 Hz, 1H, H-4’), 
4.07 – 4.10 (m, 1H, H-3’), 4.35 (t, J = 5.1 Hz, 1H, H-2’), 5.08 (t, J = 5.1 Hz, 1H, OH-5’), 5.19 (br. s, 
1H, OH-3’), 5.40 (br. s, 1H, OH-2’), 5.62 – 5.68 (m, 1H, OCH), 6.14 (d, J = 6.0 Hz, 1H, H-1’), 7.81 (s, 
1H, H-6), 8.43 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 23.29 (CH2), 23.32 (CH2), 32.36 (CH2), 
32.39 (CH2), 61.4 (C-5’), 70.4 (OCH), 74.2 (C-3’), 76.7 (C-2’), 85.3 (C-4’), 86.8 (C-1’), 102.9, 103.1, 
121.6 (C-6), 150.6 (C-7a), 151.6 (C-2), 161.7 (C-6). HRMS (ESI): calculated for C16H21ClN3O5 
([M+H]+): 370.1164, found: 370.1174. 
4-Cyclohexyloxy-5-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (40) Cyclohexanol 
(4.0 mL) was added to solid NaOtBu (0.12 g, 1.2 mmol, 4 eq.) and stirred under inert atmosphere. Then, 
48 (0.19 g, 0.30 mmol, 1eq.) was added and the resulting mixture heated to 70 °C for 2 – 3 h. After 
cooling to ambient temperature, the mixture was neutralized with 1M aq. HCl solution and evaporated 
till dryness. The residue was adsorbed onto Celite® from MeOH solution and purified by column 
chromatography 0.5 → 6 % MeOH/DCM to give 40 (0.025 g, 0.065 mmol) as a yellowish solid in 22 % 
yield. Melting point: 183 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.37 – 1.54 (m, 4H, CH2), 1.60 – 1.79 
(m, 4H, CH2), 1.89 – 1.96 (m, 2H, CH2), 3.52 – 3.56 (m, 1H, H-5’’), 3.61 – 3.66 (m, 1H, H-5’), 3.90 (q, 
J = 3.6 Hz, 1H, H-4’), 4.07 – 4.10 (m, 1H, H-3’), 4.35 (t, J = 5.7 Hz, 1H, H-2’), 5.08 (br. s, 1H, OH-5’), 
5.17 (br. s, 1H, OH-3’), 5.38 (br. s, 1H, OH-2’), 5.32 – 5.40 (m, 1H, CH), 6.14 (d, J = 6.0 Hz, 1H, H-
1’), 7.82 (s, 1H, H-6), 8.41 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 22.7 (2C), 25.1, 30.8 (2C), 
61.4 (C-5’), 70.4 (OCH), 73.2 (C-3’), 74.2 (C-2’), 85.3 (C-4’), 86.9 (C-1’), 102.9, 103.0, 121.6 (C-6), 
150.7 (C-7a), 151.7 (C-2), 161.5 (C-2). HRMS (ESI): calculated for C17H22ClN3O5 ([M+H]+): 384.1321, 
found: 384.1330. 
3’-Deoxyinosine (41)60 NaI (1.1 g, 7.5 mmol, 10 eq.) was dissolved in anhydrous MeCN (7.5 mL) and 
stirred for 5 min under argon. Next, α-acetoxyisobutyrylchloride (0.38 mL, 2.6 mmol, 3.5 eq.) was added, 
giving a white precipitate. The mixture was stirred vigorously for another 5 – 10 min, after which inosine 
(0.20 g, 0.75 mmol, 1 eq.) was added in one portion. The resulting mixture was stirred for 1.5 h after 
which TLC showed full conversion of SM. The mixture was poured in aq. sat. NaHCO3/aq. sat. Na2S2O3 
(30 mL) solution. Next, CHCl3 (30 mL) was added, and the layers separated. The water layer was 
extracted with CHCl3 (30 mL) twice more. Organic layers were combined, dried over Na2SO4, filtered 
and evaporated. The resulting oil was dissolved in MeOH (3 mL) and 1M aq. NaOAc solution (1 mL) 
was added. Next, the flask was purged with N2, after which a cat. amount of Pd(OH)2/C was added. 
Next, the N2-atmosphere was exchanged for H2 (balloon; no bubbling) and the mixture stirred overnight. 
Next, the mixture was purged with N2 to remove residual H2-gas and filtered over a pad of Celite®. The 
mixture was evaporated till dryness and partitioned between EtOAc (25 mL) and aq. sat. NaHCO3/aq. 
sat. Na2S2O3 solution (1:1, 20 mL). Layers were separated, and the water layer extracted twice more 
with EOAc (25 mL). Organic layers were combined, dried over Na2SO4, filtered and evaporated. The 
resulting oil was dissolved in 7 N NH3 in MeOH and stirred overnight. The solvent was removed, and 
the residue purified by column chromatography (2 → 20 % MeOH/DCM) to afford 41 as a white solid 
(0.062 g, 0.25 mmol) in 33% yield. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.90 (1H, ddd, J = 13.2, 6.2, 
2.1 Hz, H-3’), 2.21 (1H, ddd, J = 13.2, 9.4, 5.6 Hz, H-3’’), 3.53 (1H, m, H-5’), 3.69 (1H, m, H-5’’), 4.15 
- 4.43 (1H, m, H-4’), 4.50 (1H, br. s., H-2’), 5.03 (1H, br. s., OH-5’), 5.69 (1H, br. s., OH-3’), 5.86 (1H, 
d, J = 2.1 Hz, H-1’), 8.06 (1H, s, H-2), 8.33 (1H, s, H-8), 12.04 (1H, br. s, NH). Spectral data are in 
accordance with literature values.60  
4-Oxo-N7-(3’-deoxy-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (42) 520 (0.060 g, 0.24 mmol, 1 
eq.) was added to a 5-mL flame-dried round bottom flask equipped with a stir bar. Then, Next, 6152-53 
(2 eq.) was added, followed by anhydrous pyridine (6 mL/mmol SM). After complete dissolution of the 
solids, TMSCl (1.91 eq.) was added and the mixture heated at 100°C till full conversion of the starting 
material was observed (which was generally 24 h) The mixture was cooled to ambient temperature and 
another portion of TMSCl (2 eq.) was added. After stirring for 15 min, the mixture was evaporated till 
dryness. Next, the residue was taken up in ice-cold DCM and successively washed with brine/aq. sat. 
NaHCO3 and twice brine/aq. 1 M HCl. The organic layer was dried over Na2SO4, filtered and evaporated. 
The intermediate N6-(1,2,4-triazol-4-yl)-nucleoside was directly used in nucleophilic displacement 
reactions without further purification: 3.0 mL of aq. 1 M NaOH was added and stirred until full 
conversion was observed, yielding 42 (0.012 g, 0.048 mmol) as a white solid in 20 % yield. (Purification: 
2 → 12 % MeOH/DCM). Melting point: 248 – 250 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.90 (ddd, J 
= 13.2, 6.0, 3.0 Hz, 1H, H-3’’), 2.17 (ddd, J = 13.2, 9.0, 6.0 Hz, 1H, H-3’), 3.50 (ddd, J = 12.0, 5.7, 4.5 
Hz, 1H, H-5’’), 3.63 (ddd, J = 11.7, 5.7, 3.6 Hz, 1H, H-5’), 4.08 – 4.31 (m, 1H, H-4’), 4.32 – 4.38 (m, 
1H, H-2’), 4.94 (t, J = 5.4 Hz, 1H, OH-5’), 5.56 (d, J = 4.2 Hz, 1H, OH-2’), 6.01 (d, J = 2.4 Hz, 1H, H-
1’), 6.50 (d, J = 3.6 Hz, 1H, H-5), 7.36 (d, J = 3.6 Hz, 1H, H-6), 7.91 (s, 1H, H-2), 11.94 (br. s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6) δ: 34.8 (C-3’), 62.8 (C-5’), 75.3 (C-2’), 80.1 (C-4’), 90.4 (C-1’), 102.2 
(C-5), 108.2 (C-4a), 120.8 (C-6), 143.7 (C-7a), 147.1 (C-2), 158.2 (C-4). HRMS (ESI): calculated for 
C11H14N3O4 ([M+H]+): 252.0979, found: 252.0979. 
4-Oxo-5-bromo-N7-(3’-deoxy-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (43) 46 (0.050 g, 0.15 
mmol) was suspended in anhydrous MeCN (5.0 mL, 30 mL/mmol SM) and NaI (0.087 g, 0.58 mmol, 4 
eq.) was added. Next, TMSCl (0.075 mL, 0.58 mmol, 4 eq.) was added and the mixture stirred at ambient 
temperature till full conversion was observed by LC/MS (~approx. 1.5 h). The mixture was evaporated 
till dryness and co-evaporated with MeOH. Purification by column chromatography (1 → 15 % 
MeOH/DCM) gave 43 (0.010 g, 0.030 mmol) as a white solid in 21 % yield. Melting point: 268 °C. 1H 
NMR (300 MHz, DMSO-d6) δ: 1.86 (ddd, J = 12.9, 6.3, 3.0 Hz, 1H, H-3’’), 2.18 (ddd, J = 13.2, 8.7, 5.7 
Hz, 1H, H-3’), 3.51 (ddd, J = 12.0, 5.1, 4.2 Hz, 1H, H-5’’), 3.66 (ddd, J = 12.0, 5.4, 3.3 Hz, 1H, H-5’), 
4.25 – 4.75 (m, 2H, H-4’, H-2’), 5.00 (t, J = 5.4 Hz, 1H, OH-5’), 5.59 (d, J = 4.5 Hz, 1H, OH-2’), 5.99 
(d, J = 2.4 Hz, 1H, H-1’), 7.56 (s, 1H, H-6), 7.94 (s, 1H, H-2), 12.09 (br. s, 1H, NH). 13C NMR (75 MHz, 
DMSO-d6) δ: 34.2 (C-3’), 62.4 (C-5’), 75.3 (C-2’), 80.4 (C-4’), 90.0 (C-1’), 90.3 (C-5), 106.0 (C-4a), 
120.4 (C-6), 144.8 (C-2), 146.5 (C-7a), 157.2 (C-4). HRMS (ESI): calculated for C11H13BrN3O4 
([M+H]+): 330.0084, found: 330.0080. 
2-Amino-4-oxo-7-(3-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (44)61 NaI (0.21 g, 1.4 
mmol, 10 eq.) was dissolved in anhydrous MeCN (5 mL) and stirred for 5 min under argon. Next, α-
acetoxyisobutyrylchloride (0.072 mL, 0.47 mmol, 3.5 eq.) was added, giving a white precipitate. The 
mixture was stirred vigorously for another 5 – 10 min, after which 18 (0.040 g, 0.14 mmol, 1.0 eq.) was 
added in one portion. The resulting mixture was stirred for 1.5 h after which TLC showed full conversion 
of SM. The mixture was poured in aq. sat. NaHCO3/aq. sat. Na2S2O3 (30 mL) solution. Next, CHCl3 (30 
mL) was added, and the layers separated. The water layer was extracted with CHCl3 (30 mL) twice more. 
Organic layers were combined, dried over Na2SO4, filtered and evaporated. The resulting oil was 
dissolved in MeOH (3 mL) and 1M aq. NaOAc solution (1 mL) was added. Next, the flask was purged 
with N2, after which a cat. amount of Pd(OH)2/C was added. Next, the N2-atmosphere was exchanged 
for H2 (balloon; no bubbling) and the mixture stirred overnight. Next, the mixture was purged with N2 
to remove residual H2-gas and filtered over a pad of Celite®. The mixture was evaporated till dryness 
and partitioned between EtOAc (25 mL) and aq. sat. NaHCO3/aq. sat. Na2S2O3 solution (1:1, 20 mL). 
Layers were separated, and the water layer extracted twice more with EOAc (25 mL). Organic layers 
were combined, dried over Na2SO4, filtered and evaporated. The resulting oil was dissolved in 7N NH3 
in MeOH and stirred overnight. The solvent was removed, and the residue purified by column 
chromatography (4 → 20 % MeOH/DCM) to afford 44 as a white solid (0.0080 g, 0.030 mmol) in 21% 
yield. 1H NMR (300 MHz, D2O) δ 2.13 (ddd, J = 13.5, 6.4, 3.5 Hz, 1H, H-3’), 2.27 (ddd, J = 14.6, 8.5, 
6.4 Hz, 1H, H-3’’), 3.66 (dd, J = 12.6, 5.0 Hz, 1H, H-5’), 3.78 (dd, J = 12.0, 3.2 Hz, 1H, H-5’’), 4.39 - 
4.54 (m, 1H, H-4’), 4.58 - 4.69 (m, 1H, H-2’), 5.94 (d, J = 3.2 Hz, 1H, H-1’), 6.48 (d, J = 3.8 Hz, 1H, 
H-5), 6.94 (d, J = 3.8 Hz, 1H, H-6). Spectral data are in accordance with literature values.61 
4-Methoxy-N7-(3’-deoxy-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (45) 45 was prepared as 
described for 42: 520 (0.063 g, 0.25 mmol) was derivatized and the intermediate reacted with 6 mL of 
0.5 M NaOMe/MeOH, which yielded 45 (0.044 g, 0.16 mmol) as a white solid in 66 % yield. 
(Purification: 0.5 → 6 % MeOH/DCM). Melting point: 153 °C. 1H NMR (300 MHz, DMSO-d6) δ: 1.92 
(ddd, J = 12.9, 6.3, 3.0 Hz, 1H, H-3’’), 2.22 (ddd, J = 12.9, 8.7, 6.0 Hz, 1H, H-3’), 3.52 (ddd, J = 12.0, 
5.7, 4.2 Hz, 1H, H-5’’), 3.66 (ddd, J = 12.0, 5.7, 3.6 Hz, 1H, H-5’), 4.04 (s, 3H, OMe), 4.27 – 4.35 (m, 
1H, H-4’), 4.39 – 4.45 (m, 1H, H-2’), 4.98 (t, J = 5.4 Hz, 1H, OH-5’), 5.59 (d, J = 4.5 Hz, 1H, H-1’), 
6.14 (d, J = 2.7 Hz, 1H, H-1’), 6.56 (d, J = 3.6 Hz, 1H, H-5), 7.66 (d, J = 3.6 Hz, 1H, H-6), 8.43 (s, 1H, 
H-2). 13C NMR (75 MHz, DMSO-d6) δ: 34.7 (C-3’), 53.4 (OCH3), 62.7 (C-5’), 75.1 (C-2’), 80.1 (C-4’), 
90.4 (C-1’), 98.4 (C-5), 105.0 (C-4a), 124.5 (C-6), 150.5 (C-2), 151.3 (C-7a), 162.2 (C-4). HRMS (ESI): 
calculated for C12H16N3O4 ([M+H]+): 266.1135, found: 266.1132. 
4-Methoxy-5-bromo-N7-(3’-deoxy-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (46) 6239 (0.16 g, 
0.32 mmol) was suspended in 0.5 M NaOMe/MeOH solution (7 mL) and heated at 50 °C for 1.5 h, after 
which the solution was cooled to ambient temperature and neutralized with aq. 0.5 M HCl. Then, the 
mixture was evaporated till dryness and purified by column chromatography (1 → 5 % MeOH/DCM) 
to give 46 (0.077 g, 0.22 mmol) as a white solid in 69 % yield. Melting point: 164 – 166°C. 1H NMR 
(300 MHz, DMSO-d6) δ: 1.89 (ddd, J = 12.9, 6.0, 3.0 Hz, 1H, H-3’’), 2.22 (ddd, J = 12.9, 8.7, 6.0 Hz, 
1H, H-3’), 3.44 – 3.54 (m, 1H, H-5’’), 3.66 – 3.72 (m, 1H, H-5’), 4.06 (s, 3H, OCH3), 4.28 – 4.35 (m, 
1H, H-4’), 4.40 (br. s, 1H, H-2’), 5.04 (br. s, 1H, OH-5’), 5.62 (br. s, 1H, OH-2’), 6.13 (d, J = 2.1 Hz, 
1H, H-1’), 7.89 (s, 1H, H-6), 8.46 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6) δ: 34.1 (C-3’), 53.8 
(OCH3), 62.4 (C-5’), 75.1 (C-2’), 80.4 (C-4’), 86.1 (C-5), 90.4 (C-1’), 104.0 (C-4a), 124.0 (C-6), 150.4 
(C-7a), 151.3 (C-2), 162.2 (C-4). HRMS (ESI): calculated for C12H15BrN3O4 ([M+H]+): 344.0240, found: 
344.0231. 
4-Methoxy-5-fluoro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (51)34 4734 (0.25 g, 0.40 
mmol, 1.0 eq.) was dissolved in CH2Cl2 (1 mL). MeOH (4 mL) was added, followed by NaOMe (5.4 M 
in MeOH, 0.4 mL). After 2 h, TLC analysis indicated completion of the reaction. The reaction mixture 
was neutralized to pH 7 via the addition of 1M aq. HCl. Celite® (2 g) was added and the mixture was 
concentrated in vacuo. The residue was purified via flash column chromatography (0 → 1% 
MeOH/DCM) to afford 51 as a colourless oil (0.078 g, 0.26 mmol) in 65% yield. Spectral data were in 
accordance with literature values.34 HRMS (ESI): calculated for C12H15FN3O5 ([M+H]+): 300.0990, 
found: 300.0993. 
4-Chloro-N7-(2’,3’,5’-tri-O-benzoyl-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (52) A solution 
of 50 (0.46 g, 0.64 mmol, 1.0 eq.) in THF (10 mL) was cooled to -10°C. iPrMgCl.LiCl (1.3 M in THF, 
0.61 mL, 0.79 mmol, 1.25 eq.) was added dropwise. After 30 minutes, the reaction was poured into a 
separation funnel containing sat. aq. NH4Cl (30 mL). The mixture was extracted with CH2Cl2 (3 x 50 
mL), the combined organic phases dried over Na2SO4 and concentrated in vacuo. The residue was used 
as such in the next reaction.  
4-Chloro-5-trifluoromethyl-N7-(2’,3’,5’-tri-O-benzoyl-β-D-ribofuranosyl)-pyrrolo[2,3-
d]pyrimidine (53) TMSCF3 (0.19 mL, 1.3 mmol, 3.0 eq.) was added dropwise over the course of 1 hour 
to a suspension of CuI (0.521 g, 1.30 mmol, 1.0 eq.) and KF (0.076 g, 1.3 mmol, 3.0 eq.) in a mixture 
of dry degassed DMF/NMP 1:1 (3 mL). when all solids had dissolved, 50 (0.31 g, 0.43 mmol, 1.0 eq.) 
in dry degassed DMF/NMP 1:1 (3 mL) was added, and the mixture was heated to reflux. After 2 hours, 
LC/MS analysis showed full conversion of the starting material, and the reaction was cooled to room 
temperature. The mixture was diluted with EtOAc (15 mL) and H2O (5 mL) and the solids were filtered 
off over Celite®. The filter cake was washed extensively with additional EtOAc (3 x 25 mL), and the 
combined filtrates were transferred to a separation funnel. Additional water (40 mL) was added, the 
phases separated, and the organic phase washed twice more with water (25 mL). The organic layer was 
dried over Na2SO4 and concentrated in vacuo. The residue was purified via flash column 
chromatography (0 → 30 % EtOAc in petroleum ether) to afford 53 as a colourless oil (0.10 g, 0.15 
mmol) in 36% yield. HRMS (ESI): calculated for C33H24ClF3N3O7 ([M+H]+): 666.1249, found: 
666.1244. 
2-Pivaloylamino-4-chloro-5-bromo-N7-(2’,3’,5’-tri-O-benzoyl)-β-D-ribofuranosyl)-pyrrolo[2,3-
d]pyrimidine (54)43 2-Pivaloylamino-4-chloro-5-bromo-7H-pyrrolo[2,3-d]pyrimidine48 (0.67 g, 2.0 
mmol, 1 eq.) was suspended in anhydrous MeCN (14 mL, 7 mL/mmol SM) under argon. Then, BSA 
(0.59 mL, 2.4 mmol, 1.21 eq.) was added. The mixture was stirred for ~10 min at ambient temperature, 
after which a solution was obtained. Next, a first portion of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-
ribofuranose (0.68 g, 1.3 mmol, 0.67 eq.) was added, followed by TMSOTf (0.47 mL, 2.6 mmol, 1.3 
eq.). The resulting mixture was heated at 50 °C, and every 8 h another portion of glycosyl donor (0.67 
eq. to surmount to 2 eq.) was added. After 24 h at 50°C, the mixture was cooled to ambient temperature, 
DCM and sat. aq. NaHCO3 added. The layers were separated, and the water layer extracted twice more 
with DCM. The organic layers were combined, dried over Na2SO4, filtered and evaporated till dryness. 
Next, the residue was purified by column chromatography 100 % DCM to give 54 (1.0 g, 1.3 mmol) as 
a white foam in 65 % yield. 1H NMR (300 MHz, DMSO-d6) δ: 4.66 (dd, J = 11.7, 5.7 Hz, 1H, H-5’’), 
4.77 – 4.88 (m, 2H, H-4’, H-5’), 6.37 (dd, J = 6.0, 3.9 Hz, 1H, H-3’), 6.45 (t, J = 6.0 Hz, 1H, H-2’), 6.53 
(d, J = 3.9 Hz, 1H, H-1’), 7.40 – 7.49 (m, 6H, OBz), 7.60 – 7.68 (m, 3H, OBz), 7.89 – 7.94 (m, 6H, 
OBz), 8.07 (s, 1H, H-6), 10.38 (br. s, 1H, NH). Spectral data are in accordance with literature values.43 
2-Amino-4-chloro-N7-(2’,3’-O-isopropylidene-5’-O-tertbutyldimethylsilyl-β-D-ribofuranosyl)-
pyrrolo[2,3-d]pyrimidine (56) 5-O-tert-Butyldimethylsilyl-2,3-O-isopropylidene-α,β-D-
ribofuranose47 (0.64 g, 2.0 mmol, 1.0 eq.) was dissolved in THF (8.0 mL). The solution was cooled to -
78 °C, after which CCl4 (0.29 mL, 3.0 mmol, 1.5 eq.) was added, followed by dropwise addition of 
hexamethylphosphorus triamide (0.40 mL, 2.2 mmol, 1.1 eq.). After 15 minutes, the temperature was 
raised to -45°C to prevent solidification of the reaction mixture. After 30 more minutes, TLC analysis 
(Petroleum ether/EtOAc 8:2) indicated full conversion of the starting material. The temperature was 
further raised to 0°C and added to a premixed (30 min.) suspension of 2-amino-4-chloro-7H-pyrrolo[2,3-
d]pyrimidine (0.67 g, 4.0 mmol, 2.0 eq.) and NaH (60 wt. % in mineral oil,  0.16 g, 4.0 mmol, 2.0 eq.) 
in MeCN (30 mL). The reaction mixture was stirred overnight and concentrated in vacuo until most of 
the MeCN was removed. Water (30 mL) and EtOAc (50 mL) were added, and the mixture was 
transferred to a separatory funnel. The phases were separated and the aqueous layer extracted twice more 
with EtOAc (50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
The residue was dissolved in CH2Cl2, adsorbed onto Celite® and purified by flash column 
chromatography (Petroleum ether/EtOAc 85:15 and 8:2) to afford 56 as a yellow sticky solid (0.40 g, 
0.87 mmol) in 44% yield. HRMS (ESI): calculated for C20H32ClN4O4Si ([M+H]+): 455.1876, found: 
455.1874.  
2-Amino-4-chloro-5-bromo-N7-(2’,3’-O-isopropylidene-5’-O-tertbutyldimethylsilyl-β-D-
ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (57) 5-O-tert-Butyldimethylsilyl-2,3-O-isopropylidene-α,β-
D-ribofuranose47 (0.41 g, 1.3 mmol, 1.0 eq.) was dissolved in THF (6 mL). The solution was cooled to 
-78 °C, after which CCl4 (0.19 mL, 2.0 mmol, 1.5 eq.) was added, followed by dropwise addition of 
hexamethylphosphorus triamide (0.26 mL, 1.4 mmol, 1.1 eq.). After 15 minutes, the temperature was 
raised to -45°C to prevent solidification of the reaction mixture. After 30 more minutes, TLC analysis 
(Petroleum ether/EtOAc 8:2) indicated full conversion of the starting material. The temperature was 
further raised to 0°C and added to a premixed (30 min.) suspension of 2-amino-4-chloro-5-bromo-7H-
pyrrolo[2,3-d]pyrimidine43 (0.322 g, 1.3 mmol, 1.0 eq.), powdered KOH (0.12 g, 2.2 mmol, 1.7 eq.) and 
TDA-1 (0.042 mL, 0.13 mmol, 0.1 eq.) in MeCN (8 mL). The reaction mixture was stirred overnight 
and filtered over Celite®. The filtrate was concentrated in vacuo, and the residue dissolved in CH2Cl2, 
adsorbed onto Celite® and purified by flash column chromatography (0 → 20% EtOAc in petroleum 
ether) to afford 57 as a colourless oil (0.26 g, 0.48 mmol) in 37% yield. HRMS (ESI): calculated for 
C20H31BrClN4O4Si ([M+H]+): 533.0981, found: 533.0997. 
2-Methyl-4-chloro-N7-(2’,3’-O-isopropylidene-5’-O-tertbutyldimethylsilyl-β-D-ribofuranosyl)-
pyrrolo[2,3-d]pyrimidine (58) 5-O-tert-Butyldimethylsilyl-2,3-O-isopropylidene-α,β-D-
ribofuranose47 (1.47 g, 4.63 mmol, 1.5 eq.) was dissolved in THF (20 mL). The solution was cooled to 
-78 °C, after which CCl4 (0.672 mL, 6.94 mmol, 2.25 eq.) was added, followed by dropwise addition of 
hexamethylphosphorus triamide (0.926 mL, 5.09 mmol, 1.65 eq.). After 15 minutes, the temperature 
was raised to -45 °C to prevent solidification of the reaction mixture. After 30 more minutes, TLC 
analysis (Petroleum ether/EtOAc 8:2) indicated full conversion of the starting material. The temperature 
was further raised to 0 °C and added to a pre-mixed (30 min) suspension of 2-methyl-4-chloro-7H-
pyrrolo[2,3-d]pyrimidine (0.472 g, 3.09 mmol, 1.0 eq.), powdered KOH (0.42 g, 7.5 mmol, 2.5 eq.) and 
TDA-1 (0.49 mL, 0.55 mmol, 0.5 eq.) in MeCN (20 mL). The reaction mixture was stirred overnight 
and poured into a separation funnel containing sat. aq. NH4Cl (60 mL), H2O (30 mL). The mixture was 
extracted twice with toluene (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was 
dissolved in CH2Cl2, adsorbed onto Celite® and purified by flash column chromatography (5 % EtOAc 
in petroleum ether) to afford 58 as a colourless oil (0.68 g, 1.5 mmol) in 48 % yield. HRMS (ESI): 
calculated for C21H33ClN3O4Si ([M+H]+): 454.1923, found: 454.1934. 
2-Methyl-4-chloro-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (59)62 58 (0.68 g, 1.5 mmol, 
1.0 eq.) was dissolved in TFA (4.5 mL). H2O (0.5 mL) was added, and the mixture was stirred for 1 h 
at room temperature. The mixture was concentrated in vacuo and co-evaporated three times with toluene 
to remove all TFA. The residue was taken up in MeOH, adsorbed onto Celite® and purified by flash 
column chromatography (0 → 10% MeOH/DCM). The residue was then lyophilized to afford 59 as a 
white solid (0.19 g, 0.64 mmol) in 43% yield. 1H NMR (300 MHz, DMSO-d6) δ 2.64 (s, 3H, CH3), 3.55 
(dd, J = 12.0, 4.0 Hz, 1H, H-5’), 3.63 (dd, J = 12.0, 4.1 Hz, 1H, H-5’’), 3.93 (q, J = 3.8 Hz, 1H, H-4’), 
4.11 (dd, J = 5.1, 3.1 Hz, 1H, H-3’), 4.42 (dd, J = 6.3, 5.1 Hz, 1H, H-2’), 6.17 (d, J = 6.4 Hz, 1H, H-1’), 
6.67 (d, J = 3.8 Hz, 1H, H-5), 7.87 (d, J = 3.8 Hz, 1H, H-6). Spectral data are in accordance with literature 
values.62 
2-Methyl-4-amino-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine (60)62 A mixture of 59 (0.11 g, 
0.37 mmol, 1.0 eq.) and NaN3 (0.049 g, 0.75 mmol, 2.0 eq.) in DMF (3 mL) was heated to 80 °C. After 
5 hours, the reaction was cooled to room temperature. PMe3 (1.0M in THF, 0.93 mL, 0.93 mmol, 2.5 
eq.) and H2O (0.1 mL) were added and the reaction was stirred for another 3 hours. The mixture was 
concentrated in vacuo, and co-evaporated with toluene three times. The residue was dissolved in MeOH, 
pre-absorbed onto Celite® and purified by flash column chromatography (2 → 20% MeOH/DCM) to 
afford 60 as a white solid (0.065 g, 0.23 mmol) in 62% yield. 1H NMR (300 MHz, DMSO-d6) δ 2.40 (s, 
3H, CH3), 3.52 (dd, J = 12.0, 3.8 Hz, 1H, H-5’), 3.62 (dd, J = 12.0, 4.1 Hz, 1H, H-5’’), 3.91 (dd, J = 5.9, 
3.8 Hz, 1H, H-4’), 4.08 (dd, J = 5.0, 2.6 Hz, 1H, H-3’), 4.45 (dd, J = 6.2, 5.0 Hz, 1H, H-2’), 5.95 (d, J 
= 6.4 Hz, 1H, H-1’), 6.63 (d, J = 3.5 Hz, 1H, H-5), 7.32 (d, J = 3.8 Hz, 1H, H-6), 7.44 (br. s., 2H, NH2). 
Spectral data are in accordance with literature values.35  
1,2-Bis[(dimethylamino)methylene]hydrazine (61)52-53 Anhydrous DMF (75 mL, 70.8 g, 96.9 mmol, 
2 eq.) was added to a flame-dried round bottom flask under argon. The flask was cooled to 0 °C in an 
ice bath. After stirring at that temperature for ~20 min, SOCl2 (14.3 mL, 23.3 g, 196 mmol, 4 eq.) was 
added dropwise. After complete addition, the ice bath was removed, and the resulting mixture stirred at 
ambient temperature for 24 h. Next, aq. NH2NH2 (2.5 mL, 50 mmol, 1 eq.) as a solution in DMF (10 
mL) was added carefully in a dropwise fashion. After complete addition, the mixture was stirred at 
ambient temperature for 2 days, after which the resulting precipitate was filtered. The solids were 
washed with DMF once and subsequently with Et2O. The solid was dried under vacuum to give the 
intermediate dihydrochloride salt (8.50 g, 39.5 mmol) in 79 % yield. Next, this intermediate (4.33 g, 
20.1 mmol) was stirred with 1M aq. NaOH sol. (70 mL) for ~20 min. Then, CHCl3 (50 mL) was added, 
and the layers separated. The water layer was extracted twice more with CHCl3 (50 mL), the organic 
layers combined, dried over Na2SO4, filtered and evaporated till dryness to give 61 (2.50 g, 17.6 mmol) 
as a white solid in 87 % yield. 1H NMR (300 MHz, DMSO-d6) δ: 2.72 (s, 12H, CH3), 7.69 (s, 2H, CH). 
Spectral data are in accordance with literature values.52 
Biology 
Trypanosoma brucei 
Drug susceptibility tests with Lister 427WT, TbAT1-KO, B48 and ISMR1 were performed exactly as 
described previously,63 with the viability indicator dye resazurin (Alamar blue) in 96-well plates as the 
assay endpoint read-out. Each well contained 2×104 cells. Plates were incubated for 48 h with a doubling 
dilution series of the nucleoside test compounds in HMI-9 medium supplemented with FBS at 37 ºC/5 % 
CO2 (23 dilutions starting at 100 µM, except for the pentamidine control (50 µM)). After 48 h, resazurin 
was added to each well and the plates were further incubated for 24 h. Fluorescence was then determined 
using a FLUOstar Optima (BMG Labtech, Durham, NC) and the results fitted to a sigmoid curve with 
variable slope using Prism 5.0 (GraphPad, San Diego, Ca) to derive an EC50 value. 
Susceptibility of T. brucei Squib 427 or T. b. rhodesiense STIB-900 parasites to the nucleoside 
analogues was assayed essentially as described above except for the use of 10 concentrations of a 4-fold 
compound dilution series starting at an initial concentration of 64 µM. T. brucei Squib 427 parasites 
were seeded at 1.5×104 parasites/well while T. b. rhodesiense  parasites were seeded at 4×103 
parasites/well. After incubation for 3 days, the viability indicator resazurin was added and read-out was 
performed after incubating for another 24 h (T. brucei) or 6 h (T. b. rhodesiense). 
Cytotoxicity on MRC-5 fibroblasts17 
Drug cytotoxicity assays were performed in MRC-5SV2 human embryonic lung fibroblasts, which were 
cultured in Minimum Essential Medium with Earle’s salts-medium, supplemented with L-glutamine, 
NaHCO3 and 5% inactivated fetal calf serum. All cultures and assays were conducted at 37 °C with 5% 
CO2. To each well containing 190 µl of MRC-5 SV2 (3 x 104 cells/mL) was added the appropriately 
diluted (with water) compound (10 µL). After 3 days of incubation, cell viability was assessed 
fluorimetrically after addition of 50 L resazurin per well. After 4 h at 37 °C, fluorescence was measured 
(ex 550 nm, em 590 nm). Cell growth was determined and compared to untreated-control wells (100 % 
cell growth) and medium-control wells (0 % cell growth). The results were expressed as percentage 
reduction in cell growth / viability compared to control wells after which an EC50 was determined. 
Tamoxifen was used as reference compound (data not shown). 
Transport studies 
The inhibition of uptake of [3H]-adenosine by different concentration of test compound was performed 
by the method reported previously.64 Briefly, 50 nM 2,8-[3H]-adenosine (American Radiolabelled 
Chemicals, 40 Ci/mmol) was added to 107 bloodstream form T. brucei cells, layered on top of an oil 
layer (di-n-butylphtalate (DBH)/light mineral oil (Sigma)). After the addition of the test compound, 
uptake was terminated after 60 s by the addition of 1 mL ice-cold 250 µM unlabelled adenosine solution 
followed by immediate centrifugation through the oil layer, separating the cells from the uptake medium. 
After flash freezing in liquid nitrogen, the cell pellet was collected by cutting of the tip of the microfuge 
tube into a scintillation vial. Then, radioactivity was determined in a Hidex 300SL scintillation counter 
(Lablogic, Sheffield, UK).  
Ancillary information 
Supporting information 
Copies of 1H, 13C spectra of compounds 15, 17, 27, 29-40, 42, 43, 45 and 46 can be found in the 
Supporting Information. 
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